WO2004040302A1 - RAPL・Rap1相互作用制御 - Google Patents
RAPL・Rap1相互作用制御 Download PDFInfo
- Publication number
- WO2004040302A1 WO2004040302A1 PCT/JP2003/013937 JP0313937W WO2004040302A1 WO 2004040302 A1 WO2004040302 A1 WO 2004040302A1 JP 0313937 W JP0313937 W JP 0313937W WO 2004040302 A1 WO2004040302 A1 WO 2004040302A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- polypeptide
- amino acid
- acid sequence
- rapl
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
- G01N2333/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
Definitions
- the present invention relates to controlling the biological activity induced by interacting with P ⁇ ) (ie, RAPL).
- the present invention relates to a technique for controlling, for example, inhibiting or promoting the binding between Rapl and p30, and a technique for using the same. Tall.
- Rapl has been reported to function as an antagonist for i »H-Ras, but recently it has been revealed that it is an intracellular regulation of molecular integrins.
- Rapl positively regulates the kannity of b2-intedarin, such as LFA-1, expressed in immune cells, migrates and localizes leukocytes and vascular endothelial cells on the fiber, and expresses antigens. It has an important effect on »presenting cells.
- Such functional determination of Rapl as an integrin ## regulatory molecule is expected to be closely related to the pathological conditions of immune diseases such as inflammation, allergy, autoimmune diseases, cancer immunity, and transplant immunity.
- p30 has been identified as being involved in the control of integrins by Rapl (#Patent Document 1).
- the present invention is a.
- (1) (1) (a) an active polypeptide containing the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 2, its partial peptide or its salt, And an amino acid sequence containing the amino acid sequence substantially identical to the amino acid sequence of the amino acid sequence, which is the twelfth glycine force variant of the amino acid sequence represented by Rooster No. 2, or the point-mutated amino acid sequence.
- 'One polypeptide selected from the group consisting of awake polypeptides A polypeptide selected from the group consisting of a polypeptide containing the same or substantially the same amino acid sequence as the amino acid sequence or a partial peptide thereof or a salt thereof, and (c) a test sample;
- [2] (1) a step of contacting one polypeptide selected from the group (a), one polypeptide selected from the group (b) and a test sample,
- One polypeptide selected from the group (b), which binds to one polypeptide selected from the group (a), is a primary antibody against the polypeptide of the group (b) or the (b) (1) to (1) to (2) to detect the interaction and the formation of Z or bond of these polypeptides by detecting or measuring using a primary antibody against another peptide fused to the polypeptide of (1) to (3).
- the screening method according to any one of the above;
- one polypeptide selected from the group (a), which binds to one polypeptide selected from the group (b), is a primary antibody against the polypeptide of the group (a) or the (a) (1) to (1) to (1) to (2) to detect the formation or Z or interaction of these polypeptides by detecting or measuring using a primary antibody against another peptide fused to the polypeptide of (1) to (3).
- the screening method according to any one of the above;
- one polypeptide selected from the group (bound to one polypeptide selected from the group (a)) is a primary antibody against the polypeptide of the group (b) or Detection or measurement using a primary antibody against another peptide fused to the polypeptide and a secondary antibody against the primary antibody allows detection of the binding form and Z or interaction of these polypeptides Any one of the above-mentioned [1] to [3], wherein
- a polypeptide obtained by fusing glutathione-S-transferase to the N-terminal side of a polypeptide having an amino acid sequence represented by SEQ ID NO: 2 Alternatively, a glutamic acid-S-transferase fused to the N-terminal side of a polypeptide having an amino acid sequence which is the twelfth glycine of the amino acid sequence represented by SEQ ID NO: 2 Or a salt thereof, wherein the polypeptide of group (b) is obtained by fusing a Myc epitope on the N-5 ⁇ ⁇ side of the polypeptide having the amino acid sequence represented by SEQ ID NO: 4.
- the screening kit according to the above [9] which is a polypeptide or a salt thereof;
- a pharmaceutical composition comprising the compound of the above-mentioned [13] or a salt thereof;
- a g3 ⁇ 4 composition comprising the compound of the above-mentioned [14] or a salt thereof.
- a diagnostic method comprising using the monoclonal antibody according to [18];
- a diagnostic kit comprising the monoclonal antibody according to [18]; [21] a polynucleotide containing the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 4 A polypeptide or a salt thereof that functions as a dominant-suppressing type of intracellular peptide
- X is —CT ⁇ R 1 group or —C ( ⁇ W 1 ) W 2 R 2 group
- R 1 is an alkyl group, a haloalkyl group, an alkoxycarbonylalkyl group, an alkenyl group, a loalkenyl group, a phenyl group.
- X is an alkenylcarbonyl group substituted with an alkoxycarbonylalkylcarbinyl group, an alkenylcarbonyl group, a phenyl group, a cycloalkylcarbonyl group, an indanylcarbonyl group, a furancarbonyl group, a thiophene group.
- a medicament comprising as an active ingredient a compound having an activity of inhibiting the interaction between p30 and Rapl;
- a medicament characterized in that it contains the p30 P and the harmful agent according to the above [44] or [45] as an active ingredient;
- a medicament comprising the p30 activator according to [47] or [48] as an active ingredient
- FIG. 1 shows the amino acid sequence of p30 and its gene structure. At the same time, the amino acid sequence of Norel is also shown.
- FIG. 2 shows the cage results for the association of p30 with Rapl. This is a photograph of a chemical film exposed by the BCL luminescence method.
- FIG. 3 is (A) an electrophoresis photograph showing the results of the current distribution of p30 by RT-PCR. (B) is an electrophoretic photograph showing the results of Western blot using an anti-p30 specific antibody for various cells.
- FIG. 4 shows the results of examining the effect of if ⁇ on cell migration in which both wild-type p30 or a mutant of the p30 RBD domain and Rapl were expressed. On the right is an electrophoretic photograph showing the results of the Western plot.
- FIG. 5 shows the effect of p30 on chemokine-induced cell migration.
- Figure 6 shows (A) the effect of p30 on LFA-1 regulation.
- (B) shows the control effect of LF A-1 based on mutant p30. Only E37G, which retains the binding activity to p30, showed an increase in LFA-1 to ICAM-1.
- (C) del taNp30 suppresses adhesion of LFA-1 to ICAM-1 induced by TCR in a feed-dependent manner.
- the lower panel is an electrophoresis photograph showing the expression of deltaNp30.
- FIG. 7 shows the results of a test conducted on the effect of the compound 1 on the binding between Rapl and p30.
- Figure 8 is a micrograph showing the result of observation of the f good of the microtubule by P 30 in a confocal laser microscope «.
- FIG. 9 is a photomicrograph showing the results of local confocal laser observation of p30 and LFA-1 between T cells and antigen presenting cells.
- the relevant predecessor activities include microtubule or microtubule induction, leading edge and / or uropod formation, and increased LFA-1 activity
- Chemokine stimulation increases T cell migration activity, increases cell proliferation, induces cell migration, redistributes CXCR4 and / or CD44 (redistri but ion) antibody to T cell receptor (TCR) complex Pollution of cells by cross-linking of the body or cross-linking of chemokines, clustering at the leading edge of LFA-1, polarization of LFA-1, Localization, clustering of LFA-1 at the leading edge and co-localization of P30, formation of conjugates between antigen-presenting cells (APCs) and LFA- Co-accumulation of 1 and p30, Integrin-dependent promotion of migration ability, T cell polarity formation, T cell SMA formation, and the like.
- APCs antigen-presenting cells
- ⁇ 'p30 was named RAPL (regulator for cell adhesion and polarization enriched in lymphoid tissues) (Koko Katagiri et al., Nature Immunol ogy s August 4, 2003 (8): 741-748) .
- p30 and RAPL are the same polypeptide and have an amino acid sequence represented by Rooster J number: 4. In the following description, p30 indicates MPL.
- p30 is biological activities involving Les, the force anything ability to detect or measure the interaction between the detection or P 30 be cowpea to measuring the active 's Awakening Rapl the Zureka. If this technology is used, the interaction between 30 and alive Rapl and Z or bond cranes ij or An accelerator can be screened, and a drug can be developed using the identified inhibitor or accelerator. According to the present technology, it is also possible to regulate the binding between P30 and active Rapl and to control the interaction between them, and to regulate impeachment and screening of compounds involved in the regulation. It is possible to study various physiological phenomena and biological activity phenomena, and it is possible to develop pharmaceuticals related to them.
- the interaction and / or binding between the active tt polypeptide of the polypeptide Rap1 represented by SEQ ID NO: 2 and the polypeptide p30 represented by SEQ ID NO: 4 is inhibited or inhibited by the I3 ⁇ 4S technique.
- a method for screening a promoting compound comprises the steps of: (a) an active polypeptide containing the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 2, a partial peptide thereof or a salt thereof;
- the amino acid sequence represented by the amino acid sequence represented by No. 2 is an active polypeptide containing an amino acid sequence in which the glycine at position 12 is valine or an amino acid sequence substantially identical to the point-mutated amino acid sequence.
- polypeptide selected from the group consisting of one polypeptide selected from the group or a partial peptide thereof or a salt thereof) or the same or substantially the same as the amino acid sequence represented by Rooster No. 4 Screening test in the presence of one polypeptide selected from the group consisting of a polypeptide containing an amino acid sequence or a partial peptide thereof or a salt thereof This is done by coexisting the sample.
- the polypeptide of the above-mentioned group (a) or the polypeptide of the above-mentioned group (b) those obtained as recombinant proteins by genetic and recombination techniques are used, and these polypeptides are used. It is also possible to use a co-expressed cell or an extract thereof.
- the active ft polypeptide of the group (a) refers to a polypeptide that can bind to p30.
- the polypeptides of group (a) in the active form are prepared using GTP or GTP analog such as GTP JS or GppNHp in a buffer solution. By treating at ⁇ 37 ° C for 10 minutes and for 1 hour, it can be more active. Activation by GTP analogs such as GTPyS and GppNHp is preferable, and activation by GTPyS is more preferable.
- the polypeptide of group (a) is expressed intracellularly: ⁇ indicates that the cell is cross-linked to a T-cell receptor-1 (TCR) complex by an antibody. It is the ability of the polypeptide to become an active garden by dispersing.
- TCR T-cell receptor-1
- the cross-linking of the TCR complex with an antibody can be an example of IJ intensification by treatment with an anti-CD3 monoclonal antibody.
- chemokine-induced IJ intensities include treatment with SLC (secondary y lymphoid tissue chemokine), CCL21 (chemokine cc motif ligand 21), and SDF-1 (stromal cel l-derived factor-1).
- SLC secondary y lymphoid tissue chemokine
- CCL21 chemokine cc motif ligand 21
- SDF-1 stromal cel l-derived factor-1
- the ability to screen a test sample by various methods for example, (l) (a) the amino acid sequence represented by the rooster sequence number: 2 An active polypeptide containing the same or substantially the same amino acid sequence as the above, or a partial peptide thereof or a salt thereof, and valine is the twelfth daricin in the amino acid sequence represented by SEQ ID NO: 2.
- a method for coexisting the polypeptide of the group (a), the polypeptide of the group (b) and the test sample a method of simultaneously contacting three persons, Or the polypeptide of (b).
- Use cells that co-express these polypeptides choose these methods by adjusting the timing of expression of each polypeptide and the timing of contact between test samples and IT cells It is possible to do.
- substantially the same amino acid sequence means about 70% or more, preferably about 80% or more, more preferably 90% or more, Preferably, it refers to an amino acid sequence having about 95% or more homology.
- the original amino acid sequence of “the amino acid sequence substantially identical to the amino acid sequence represented by SEQ ID NO: 4” is the amino acid sequence represented by SEQ ID NO: 4.
- Polypeptide containing an amino acid sequence substantially identical to an amino acid sequence is a polypeptide containing the aforementioned “substantially identical amino acid sequence” and having the original amino acid sequence. Polypeptides substantially the same as the above are preferred. In the present invention
- substantially equivalent means that the activities of the proteins, eg, binding activity, physiological activity, and biological activity are substantially the same. Furthermore, the meaning of the term also includes those having substantially the same activity. Examples of the substantially same activity include control of cell 3 ⁇ 43 ⁇ 4, cell migration, cell polarization, and the like. I can help you. Said substantially equivalent activities indicate that those activities are of the same nature in nature. For example, activities such as binding activity are equivalent (eg, about 0.001 to about 1000 times, preferably about 0.01 to about 100 times, more preferably about 0.1 to about 20 times, and more preferably (About 0.5 times to about 2 times), but the quantitative factors such as the degree of these activities and the molecular weight of the protein may be different.
- binding activity are equivalent (eg, about 0.001 to about 1000 times, preferably about 0.01 to about 100 times, more preferably about 0.1 to about 20 times, and more preferably (About 0.5 times to about 2 times), but the quantitative factors such as the degree of these activities and the molecular weight of the protein may be different
- the polypeptide of the group (a) or the group (b) of the present invention may be one having a preferable change such as amino acid substitution, deletion, insertion, addition, or the like. Characteristics or chemical characteristics may be changed.
- the polypeptide having the substitution, deletion, insertion or addition may be one which is assumed to be substantially the same as that having no such substitution, deletion, insertion or addition.
- Substantially identical substitutes for the amino acid in the amino acid sequence may be selected from other amino acids of the class to which the amino acid belongs.
- examples of @ (hydrophobic) amino acids include alanine, phenylalanine, leucine, isoleucine, valine, proline, tributofan, and methionine
- polar (neutral) amino acids include glycine, serine, threonine, and the like.
- examples include cystine, tyrosine, asparagine, and glutamine.
- examples of positively charged amino acids include arginine, lysine, and histidine.
- examples of negatively charged amino acids (acidic amino acids) include Aspartic acid, glutamic acid and the like.
- the polypeptide of the present invention can modify the amino acid residue contained in the polypeptide by a ligological method, and can also be used for peptidases, such as pepsin, chymotrypsin, papain, bromelain, and endopeptidase. It can be modified by using enzymes such as zeo or exopeptidase, or partially degraded to make it a destructive book.
- a photographic peptide or polypeptide (or protein) is one in which one or more amino acid residues differ from the natural one in terms of identity, It may be different.
- One or more amino acid residues in Rapl or p30 protein for example, 1 to 80, preferably 1 to 60, more preferably 1 to 40, more preferably 1 to 20, particularly 1 ⁇ 10) Missing Missing ⁇ !
- One or more of the analogs or unique amino acid residues eg, 1 to 80, preferably 1 to 60, more preferably 1 to 40, more preferably 1 to 20, especially 1 to 10 Etc.
- Addition analogs having up to 20 amino acids, especially 1 to 10 amino acid residues, and 1 or more (for example, 1 to 80, preferably 1 to 60, more preferably 1 to 10) Insertions having 40, more preferably 1 to 20, especially 1 to 10) amino acid residues are also included in the polypeptides of the present invention.
- the position of the amino acid sequence insertion, deletion or substitution that is inserted, deleted or substituted is not particularly limited.
- test sample can be screened based on the inhibition of the binding between Rapl and p30, instead of the biological activity as the interaction between Rapl and p30.
- the polypeptide of group (a) used for tf ⁇ is not particularly limited as long as it has an activity of binding to wild-type p30.
- the amino acid sequence represented by SEQ ID NO: 2 is an amino acid sequence modified by substitution, deletion Z or addition of an amino acid residue as described above. It may be a polypeptide having There is no particular limitation on the polypeptide of group (b) which is i ⁇ ffl to ⁇ as long as it has an activity of binding to wild-type Rapl. It may have lost the biological activity of p30.
- Test samples include, for example, proteins, peptides, non-peptidic compounds, synthetic compounds, fermentation products, plant extracts, wild extracts of animals, etc., and cell extracts.
- test compound used in the test sample may preferably include an anti-p30 antibody, an enzyme inhibitor, a cytotoxic agent, a compound having various inhibitory activities, particularly a synthetic compound, and the like. These compounds may be new compounds or known compounds. Representative compounds include, for example, various diamino trifluoromethyl pyridine derivatives disclosed in JP-A-6-263735. The screening can be performed according to a conventional method for measuring binding activity or biological activity.
- any of the active polypeptides in the group (a), the polypeptides in the group (b), and a test sample are brought into contact with each other.
- the interaction between the polypeptides of both groups is detected by detecting or measuring the biological activity involving p30, and the selection is made of a compound that promotes or inhibits the interaction between the polypeptides. Screening purified compounds, etc .: t ⁇ may be omitted in the selection step.
- the predecessor activity involving P30 includes microtubule development or microtubule development. Induction, leading edge and / or uropod form) ⁇ induction, increase of LFA-1 3 ⁇ 4 # activity, increase of T cell migration activity by chemokine stimulation, increase of cell adhesion Induction of cell migration, CX—CR 4 and / or CD44 redistribution, antibody-mediated cross-linking of T cell complex receptor (TCR) complex (TCR) complex or chemokine, etc.
- TCR T cell complex receptor
- TCR TCR complex receptor
- Another embodiment of the screening method of the present invention is that the polypeptide of any of the active #S in the group (a), the polypeptide in the group (a), and the test sample are brought into contact with each other. It is performed by detecting the formation of the polypeptide bonds of the group and selecting a compound that promotes or inhibits the formation of 13 ⁇ 4Yoshigo. Screening purified compounds, etc .: ff ⁇ , the selection step may be omitted. If activation of the polypeptide of group (a) is necessary, use GTP inducer as described above. When the polypeptide is immobilized on the solid phase, activation may be performed before or after immobilization, but more preferably after immobilization.
- the polypeptide used in the present invention can be used by binding to an adjuvant book.
- the polypeptide may be immobilized on the support by a standard method.
- the bond to which the polypeptide is bound include insoluble polysaccharides such as agarose, dextran, cellulose, and synthetic resins such as polystyrene, polyacrylamide, and silicon. More specifically, commercially available beads and plates manufactured using them as raw materials are used. If ⁇ of the beads, these strongly packed columns or the like may be used. Plate of multiwell Plates (96-well multi-well plate, etc.) and biosensors per chip o
- a commonly used method utilizing a ligand bond, physical adsorption, or the like may be used.
- an antibody that specifically recognizes the polypeptide can be bound to a branch tree in advance, and the antibody can be bound to the polypeptide.
- binding can be enhanced via avidin / pyotin.
- the binding between the polypeptide of the group (a) and the polypeptide of the group (b) is usually performed in a buffer.
- a buffer for example, a phosphate buffer, a Tris buffer, or the like is used.
- Incubation conditions include conditions that have already been used, for example, incubating at 4 ° C to room temperature for 1 second to 3 hours, preferably 3 seconds to 2 hours, more preferably 10 seconds to 30 minutes. Chillon is strongly mentioned. Washing after the incubation is not particularly limited as long as it does not hinder protein binding.
- a buffer containing a surfactant is used.
- a surfactant for example, 0.05% Tween20 is used.
- specific binding is performed by incubating the polypeptide of the group (a), the polypeptide of the group (b) and the test sample under appropriate conditions, and then washing. And the ability to separate extraordinary bonds. What is necessary is just to face the bonding state between the polypeptide of the group (a) and the polypeptide of the group (b).
- the polypeptide to be bound to the support book may be either the polypeptide of the group (a) or the polypeptide of the group (b). That is, the polypeptide of the above (a) group is bound to an adjuvant book: l ⁇ contains the polypeptide of the above (a) group after immobilization, and is combined with the polypeptide of the above (b) group.
- the test sample may be mixed in advance, or the polypeptide of group (b) may be added after the test sample is added.
- the age at which the polypeptide of group (b) is immobilized on a support is also determined by mixing the polypeptide of group (a) with a test sample in advance or after adding the test sample.
- Polypeptides of the group may be added.
- the polypeptide of the group (a), the polypeptide of the group (b) and the test sample added in the above order are incubated under appropriate conditions, and the polypeptide of the group (a) and the polypeptide are added.
- a control group may be provided together with a group in which the test sample is brought into contact with the polypeptide.
- a negative control group and / or a positive control group that does not contain the test sample can be used.
- the bound polypeptide When detecting or measuring the bound polypeptide in the present invention, the bound polypeptide may be simply detected, or the bound polypeptide may be quantitatively measured. By comparing these ii ⁇ , the results obtained in the negative control group without the test sample, the results obtained in the group containing the test, and the results obtained in the Z or random control group, The ability to detect
- results can be obtained as numerical values, and by comparing those numerical values, the activity of the target compound can also be measured.
- the ability to detect the target compound by comparing the values obtained in the control group without the test sample with those obtained in the group to which the test sample was applied. I can do it. If the obtained value increases or decreases as compared to the shade, it can be determined that the test sample contains the target.
- a cryptic control group containing a known amount of a compound which is strongly known to inhibit the binding of the polypeptide of group (a) to the polypeptide of group (b) Can be based on the standard curve created by the numerical values obtained in. When the amount of bound polypeptide is large, the activity of the compound that inhibits the binding of the polypeptide is low, while the amount of bound polypeptide is small, the binding of the polypeptide is reduced.
- a biosensor utilizing the surface plasmon resonance phenomenon can be used as a means for detecting or measuring the bound polypeptide.
- a sensor using the surface plasmon resonance phenomenon can observe the interaction between polypeptides in real time as a surface plasmon resonance signal without labeling the interaction between the polypeptides.
- a biosensor such as BIAcore. That is, a cell obtained by immobilizing one of a combination of the polypeptide of the group (a) and the polypeptide of the group (b). The other polypeptide of the combination is brought into contact with the sensor chip, and the polypeptide that binds to one of the immobilized polypeptides is detected as a change in resonance signal.
- the sensor chip CM5 (manufactured by Biosensor) is activated to immobilize one of the combination of the ⁇ group polypeptide and the (b) group polypeptide on one sensor chip. That is, after the sensor chip was activated with an EDC / NHS aqueous solution (2 OOmM BDC (N-ethyl-N '-(3-dimethylaminopropyl) carbonate hydrochloride), 50 mM NHS (N-hydroxysuccinimi de)), the HBS buffer was removed. Wash the sensor chip with buffer (10 mM HEPES pH 7.4, 150 mM NaCl, 3.4 mM EDTA, 0.05% Tween20).
- buffer 10 mM HEPES pH 7.4, 150 mM NaCl, 3.4 mM EDTA, 0.05% Tween20).
- an appropriate amount of the interacting polypeptide dissolved in the HBS buffer is brought into contact with the sensor chip and immobilized. After washing the sensor chip with an HBS buffer, the remaining activity on the sensor chip is blocked with an ethanolamine solution (1 M ethanolamine chloride, pH 8.5). Wash the sensor chip again with HBS buffer and use for binding Wjffi. Next, an appropriate amount of the polypeptide dissolved in the HBS buffer is injected. At this time, the amount of the polypeptide having an interaction that binds to the polypeptide immobilized on the sensor chip is observed as an increase in the resonance signal value.
- a test sample is injected into the other polypeptide having an interaction with one of the polypeptides.
- a control group may be set up together with the group into which the test sample is injected.
- the control group can include a negative control group, a positive control group, or both groups that do not contain the test sample.
- the bound polypeptide can be measured as a change in resonance signal value. This: ti ⁇ , by comparing the results obtained with the group of negative controls without the test sample, the results obtained with the group containing the test sample and / or the results obtained with the positive control group The ability to detect and determine the target compound.
- a means for detecting or measuring the bound polypeptide it is possible to label the polypeptide I, or to use the label of the bound polypeptide. For example, in the above-described screening method, one of the polypeptides was added together with the test sample. The other polypeptide to be brought into contact with the sample is labeled in advance, and the sample is incubated with the test sample, and then washed to detect the bound polypeptide.
- test sample and the other labeled polypeptide are preferably brought into contact with one of the polypeptides bound to the support. After incubating, the plate may be washed, and the label of the bound polypeptide may be detected or measured.
- the polypeptide used in the present invention can be labeled by a generally known method.
- the labeling substance include radioisotope, enzymes, fluorescent substances, biotin / avidin and the like.
- labeling substances commercially available labeling substances can be used.
- radioisotopes for example 3 2 P, 3 3 P, 1 3 1 1, 1 2 5 I, 3 H, 1 4 C, 3 5 S and the like.
- the enzyme include alkaline phosphatase, horseradish powder (HRP), 3 galactosidase, and 3 / 3-glucosidase.
- the fluorescent substance include fluorescein isothiocyanate (FITC) and rhodamine power.
- the substrate is added, and the enzymatic change of the substrate, for example, color development is detected or measured by an absorbance meter.
- Fluorescent substance ⁇ Detected or measured by fluorimeter.
- one of the polypeptides of the group (a) and the polypeptide of the group (b) is specifically recognized by a combination of the polypeptides.
- the primary antibody is preferably labeled with a labeling substance. Specifically, it can be performed as follows. That is, add an intense night containing some polypeptide to the plate and place it. After washing the plate, block with, for example, BSA to prevent nonspecific binding of the polypeptide. Wash again and add the test sample and the other polypeptide to the plate. At the same time, place a negative control group containing no test sample and a Z or positive control group, and incubate them. After the incubation, wash and add the antibody against the polypeptide added with the test sample. After a suitable incubation, the plate is washed and the polypeptide is detected or measured with a primary antibody that specifically recognizes the polypeptide.
- 3 ⁇ 4 isotope of dimensional isotope is detected or measured by liquid scintillation.
- its substrate is added, and the enzymatic change of the substrate, for example, color development is detected or measured by an absorptiometer.
- Detect or measure with a fluorometer for fluorescent substances By comparing these results with the values obtained in the control group, the target compound can be determined.
- a primary antibody that specifically recognizes another peptide fused to the polypeptide used in the present invention can be used as a means for detecting or measuring the bound polypeptide.
- the other polypeptide is brought into contact with the other polypeptide along with the test
- the peptide is detected or measured with a primary antibody that specifically recognizes the other peptide fused to the polypeptide. That is, preferably, a test funnel and the other polypeptide are attached to one of the polypeptides bound to the book. After incubating, washing and binding, the other polypeptide is fused with the polypeptide and features other polypeptides. What is necessary is just to detect or measure by the primary antibody which recognizes differently.
- the primary antibody is preferably labeled with a labeling substance. Specifically, you can do the following: That is, a pool containing any of the polypeptides is added to the plate and left overnight. After washing the plate, e.g. B to prevent differential binding of the polypeptide
- Block with SA Wash again and add the test and the other polypeptide fused to the other peptide to the plate. At the same time, place a negative control group containing no test sample and a Z or positive control, and incubate them. After the incubation, the antibody is washed, and an antibody against another peptide fused with the polypeptide added together with the test sample is added. After an appropriate incubation, the plate is washed and the polypeptide is detected or measured with a primary antibody that specifically recognizes the other peptide fused to the polypeptide. For detection or measurement, detection or measurement is performed using liquid scintillation of the same element.
- the enzyme's substrate is added, and the enzymatic change of the substrate, eg, color development, is detected or measured by an absorptiometer.
- absorptiometer For fluorescent substances: Detect or measure with a fluorometer.
- the target compound can be determined by comparing these results with the values obtained in the control group.
- a primary antibody that specifically recognizes the polypeptide to be ifffled in the present invention and a secondary antibody that specifically recognizes the primary antibody. it can.
- one of the polypeptides is brought into contact with the other polypeptide together with the test sample, incubated with the test sample, and then washed to separate the bound polypeptide into a specific one.
- Detection or measurement is performed using a primary antibody that recognizes the above and a secondary antibody that specifically recognizes the primary antibody. That is, a sample and another polypeptide are preferably brought into contact with one of the polypeptides bound to the book.
- the polypeptide may be detected or measured with a primary antibody that specifically recognizes the polypeptide and a secondary antibody that specifically recognizes the primary antibody.
- the secondary antibody is preferably labeled with a labeling substance. Specifically, it can be performed as follows. That is, a pool containing some polypeptide is added to the plate and left overnight. After washing the plate, block it with eg BSA to prevent unusual binding of the polypeptide. Wash again and remove the test sample Add the other polypeptide to the plate. At the same time, place a negative control group containing no test sample and a Z or positive control group, and incubate them.
- the antibody is washed and a primary antibody against another peptide fused with the polypeptide added together with the test sample is added. After a suitable incubation, the plate is washed and then a secondary antibody that specifically recognizes the primary antibody is added. After appropriate incubation, washing is performed, and the polypeptide is detected or measured by a secondary antibody that specifically recognizes a primary antibody that specifically recognizes the polypeptide. For detection or measurement, detect or measure by liquid scintillation of 4 dimensional diisocyanate. In the case of an enzyme, the substrate is added, and the enzymatic change of the substrate, for example, color development is detected or measured by an absorbance meter. Age of fluorescent substance, Detected or measured by fluorometer. By comparing these results with the values obtained in the control group, it is possible to select the target compound.
- a primary antibody that specifically recognizes another polypeptide fused with the polypeptide and a secondary antibody that specifically recognizes the primary antibody are used.
- I can be powerful.
- one of the polypeptides is inoculated with one of the polypeptides together with the test sample, incubated with the test 1 ⁇ , and then washed and bound.
- Detection or measurement is performed using a secondary antibody that specifically recognizes the antibody and the primary antibody. That is, the test sample and the other polypeptide are preferably brought into contact with one of the polypeptides, preferably bound to a strip. After incubation, the plate may be washed and then detected or measured with the bound primary antibody and a secondary antibody that specifically recognizes the primary antibody.
- the secondary antibody is preferably labeled with a labeling substance.
- the plate is washed, and the polypeptide is detected or measured by a secondary antibody that specifically recognizes a primary antibody that specifically recognizes another polypeptide fused to the polypeptide.
- a secondary antibody that specifically recognizes a primary antibody that specifically recognizes another polypeptide fused to the polypeptide.
- radioactive isotope liquid scintillation For detection or measurement, use radioactive isotope liquid scintillation to detect or measure.
- the enzyme's substrate is added and the enzymatic change of the substrate, eg, color development, is detected or measured by an absorptiometer. It is detected or measured with an age fluorescent meter of the fluorescent substance. By comparing these results with the values obtained in the control group, the target compound can be determined.More specifically, the present invention is particularly preferably carried out by ELISA (Enzyme-linked Immunosorbent Assay).
- each well was washed three times with the washing buffer, and the polypeptide of the group (b) fused with another peptide, for example, FLAG, diluted with a dilution buffer (1% BSA, 0.5% Tween 20, PBS).
- a dilution buffer 1% BSA, 0.5% Tween 20, PBS.
- wash buffer 100 ⁇ l of Algaric phosphatase-labeled goat anti-mouse IgG antibody (manufactured by ZYMED) diluted 1000-fold with dilution buffer to each well, and add 1 hour at room temperature. Incubate. With wash buffer one was washed 5 times each well a chromogenic soluble liquid (substrate buffer;. Ltd.
- the screening method of the present invention can use High Throughput Screening (HTS). More specifically, up to blocking can be performed manually, and the subsequent reactions can be automated using robots, which can be used to realize high throughput screen in. That is, other peptides, for example, the fused with 6 xHis (a) a group of the polypeptide to immobilized buffer (0. 1M NaHC0 3, 0. 02 % NaN PH9. 6) by dilution. This water pool diluted in each well of a 96-well Imno plate (manufactured by Nunc) is subjected to proper incubation at 4 ° C.
- HTS High Throughput Screening
- EL404 microplate washer manufactured by Bio Tek
- a SPECTRA max 250 plate reader (Molecular Devices) can be used.
- the program is set to perform the following operations. That is, wash each well three times with the washing buffer, and mix the test sample with another peptide diluted with dilution buffer (1% BSA, 0.53 ⁇ 4 Tween20, PBS), such as MBP (maltose binding polypeptide).
- dilution buffer 1% BSA, 0.53 ⁇ 4 Tween20, PBS
- MBP maltose binding polypeptide
- a commercially available antibody or an antibody contained in a commercially available kit can be used as the antibody to be ffflfled, and a monoclonal antibody or a polyclonal antibody obtained by known means can also be used.
- the monoclonal antibody is used to ifffl a desired sensitizing antigen, immunize it according to a conventional immunization method, fuse the obtained cell-free cells with a known parent cell by a conventional cell fusion method, and perform a conventional screening. It can be prepared by screening monoclonal antibody producing cells by the method.
- a combination of the polypeptide of the above-mentioned group (a) and the polypeptide of the above-mentioned group (b) may be used to detect both polypeptides.
- FRET fluorescence resonance energy transfer between fluorescent proteins
- Fluorescence resonance energy transfer between adjacent fluorescent protein molecules Is used to detect the binding between the polypeptides of groups (a) and (b), for example, the fusion of the polypeptide of group (a) with the yellow fluorescent protein (YFP).
- YFP yellow fluorescent protein
- Click protein (CFP) and YFP and CFP fusion polypeptides contacting the. Both groups of the polypeptide is fused to any if binding of a state of close proximity.
- Fluorescence resonance energy transfer is based on the two-molecule system as described above, as well as the fusion polypeptide of the (a) group and the yellow light photoprotein (YFP) in one molecule.
- Peptide and ⁇ Fluorescent Protein (CFP) Occurs in molecules that exist between powerful molecules, and the detection sensitivity in this case can be adjusted by adjusting the length of the molecules It is.
- CFP Fluorescent Protein
- the above-mentioned fusion polypeptide with the fluorescent protein is expressed in the cell (co-expression of the two-molecule system).
- the cell can be used for the screening of the present invention. It is possible to simultaneously perform the detection or measurement of the binding of the polypeptides of the groups (a) and (b) and the detection or measurement of the biological activity involved in p30.
- 1 N. Mochizuki et al. Nature vol. 411: 1065-1068, edited by Atsushi Miyawaki GFP and bioimaging Cells that can be performed according to the method described in Yodosha and can be used for screening
- the above-described detection or measurement can be performed by cultivating the DNA in the presence or absence of a test sample.
- polypeptide may refer to any of the polypeptides described below. The basic structure of polypeptides is well known and is described in numerous references and other publications in the art.
- polypeptide as used herein is intended to include any amino acid containing two or more amino acids such that they are linked to each other by a peptide bond or a modified peptide bond. Or any protein.
- polypeptide includes in the art, for example, short chains also referred to as peptides, oligopeptides, or peptide oligomers, and proteins that are commonly referred to as many forms. Both long-strength ones that are well known may usually mean.
- Polypeptides may often contain amino acids other than amino acids, which are usually referred to as natural amino acids (natural amino acids: or gene-encoded amino acids).
- Polypeptides may also be processed and otherwise altered (or modified) after many of their amino acid residues, including the terminal amino acid residue, have been translated, and only by natural processes. It will be understood that the above polypeptides can be modified (modified) by chemical modification techniques well known to those skilled in the art. Modifications made to the polypeptide
- Modification is described in many forms, and they are described in detail in basic reference books and more detailed articles in the art, as well as in many research literatures. Is well known. Especially the usual modification of the power For example, alkylation, acylation, esterification, amidation, glycosylation, lipid binding, sulfation, phosphorylation, carboxylation of glutamic acid residue, hydroxylation and ADP-ribosylation, etc. For example, TE Creighton, Proteins-Structure and Molecular Properties, Second Edition, WH Freeman and Company, New
- Representative P30 proteins of the present invention include the amino acid sequence of the polypeptide of FIG. 1 or a polypeptide having an amino acid sequence substantially equivalent thereto, for example, at least 5 amino acids of the amino acid sequence. Has up to 213 consecutive amino acid residues and has a biological activity including substantially equivalent biological activities such as Rapl binding activity ttX having a dominant inhibitory function, equivalent antigenicity, etc. Or at least 50% homology, or at least more than 60%, homology, or at least 70% homology with each one of the domains of FIG. Or at least 80% homology, or at least 90% homology, or at least 95% homology, or at least 98% homology Shall, etc., and force new ones.
- substantially equivalent biological activities such as Rapl binding activity ttX having a dominant inhibitory function, equivalent antigenicity, etc.
- the number is preferably at least 80, more preferably at least 90, most preferably at least 100, and more preferably at least 110.
- P30-related ports of the present invention 11 May have a portion of the amino acid sequence of FIG. 1 or may have a Met corresponding to the start codon. Any having such an arrangement may be included.
- the nucleic acid encoding the P30 protein or the polypeptide to be treated in the present invention typically encodes the peptide shown in FIG. 1 and a part of the contiguous amino acid sequence thereof.
- Those containing a base sequence, or containing a base sequence composed of at least the H region of the peptide code of the base sequence (including those that code only specific domains) codes A sequence in which a start codon (codon for coding Met) and a stop codon are added, and the base sequence has an amino acid sequence having at least 50% homology with the protein to be coded, and FIG. Has at least a specific amino acid residue which is closely related to the amino acid sequence, and the Rapl-binding activity ttX has a dominant-suppressing function.
- the biological activity of Meta may be any so long as it contains the same effect of the nucleotide sequence and which was at the a peptide co Solo de with biological activity.
- the nucleic acid encoding the protein is a single-stranded DM, , RNA, DNA: Nucleic acids such as RNA hybrids and synthetic DNAs, and may be any of human genomic DNA, human genomic DNA library, cDNA derived from human paper tissue cells, and synthetic DNA.
- the base sequence of the nucleic acid encoding the protein can be modified (eg, added, removed, substituted, etc.), and such modified ones can be included.
- the nucleic acid of the present invention may encode the peptide of the present invention or a part thereof, and is preferably DNA.
- the “equivalent base sequence” refers to, for example, 5 or more base sequences, preferably 10 or more base sequences, more preferably 15 or more base sequences of the base sequence under stringent conditions. And more preferably those which hybridize with a base sequence of 20 or more nucleotides and encode an amino acid sequence substantially equivalent to the protein.
- One embodiment of a method for obtaining and isolating a functionally equivalent protein is as follows: Methods for introducing mutations into amino acids in protein are well known to those skilled in the art.
- proteins are usually within 50 amino acids of all amino acids, preferably within 30 amino acids, more preferably within 10 amino acids, and even more preferably within 3 amino acids.
- Amino acid modification can be performed, for example, by using “Transformer Site-directed uta genesis Kit” or “Excite PGR-Based Site-directed Mutagenesis Kit” (manufactured by CI ontech) for mutation or substitution. If it is a deletion, it can be done by using "Qimntum leap Nested Deletion Kitj (Clontech ⁇ ⁇ )". , “Chemical Experiment Course 1, Genetic Research Method II”, P105 (Susumu Hirose), Tokyo Kagaku Dojin (1986); Japanese Biochemical Society, “New Biochemical Experiment Course 2, Nucleic Acid III (Recombinant DNA Technology)”, p233 OS Susumu), Tokyo Kagaku Doujin (1992); R. Wu, L.
- site-directed mutagenesis using a synthetic oligonucleotide (site-directed mutagenesis) (Zoller et al., Nucl. Acids Res., 10: 6487, 1987; Carter et al., Ucl. Acids Res. , 13: 4331, 1986), cassette mutagenesis (Wells et al., Gene , 34: 315, 1985), restriction selection mutagene sis: Wells et al., Phi los. Trans. R. Soc. London Ser A, 317: 415, 1986), alanine.scan.
- substantially the same activity indicates that those activities are of the same nature in nature, for example, that they are physiologically, pharmacologically or biologically equivalent.
- activities such as binding activity are equivalent (for example, about 0.001 to about 1000 times, preferably about 0.01 to about 100 times, more preferably about 0.1 to about 20 times, and more preferably about 0.1 to about 20 times. (0.5 to about 2 times), and the quantitative factors of these activities, such as Mg and protein molecular weight, may be different.
- the peptide (X is a polypeptide) When the peptide (X is a polypeptide) is obtained as a non-active form, it can be converted into a salt by a method known per se or a method analogous thereto, and At the age obtained as a salt, it can be converted to an awake or another salt by a method known per se or a method analogous thereto.
- the salt of the peptide (or polypeptide) is physiologically acceptable or pharmaceutically acceptable, but is not limited thereto.
- examples of such salts include salts with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, and phosphoric acid. ⁇ , ⁇ , maleic acid, fumaric acid, succinic acid, cunic acid, tartaric acid, malic acid, salts with organic acids such as benzoic acid, methanesulfonic acid, P-toluenesulfonic acid, benzenesulfonic acid and the like.
- examples of the salt include an ammonium salt, for example, a salt with an organic base such as ethylamine, dimethylamine, trimethylamine, and hydroxyethylamine.
- an ammonium salt for example, a salt with an organic base such as ethylamine, dimethylamine, trimethylamine, and hydroxyethylamine.
- it is expressed as a fusion protein when produced by a genetic engineering method, and has a biological activity substantially equivalent to that of a natural protein of the present invention in vitro or in vivo. Converted ⁇ May be processed. The ability to use fusion production methods commonly used in genetic engineering. These fusion proteins can be purified by affinity mouth chromatography using the fusion.
- Such fusion proteins include those fused to a histidine tag, ⁇ -galactosidase (/ 3-gal), maltose-binding protein (MBP), glutathione-S-transferase (GST), Examples include those fused to the amino acid sequence of thioredoxin (TRX) or Cre Recombinase.
- a polypeptide can be tagged with a heterogeneous epitope, such that purification by immunoaffinity chromatography using an antibody that specifically binds to the epitope can be accomplished.
- the epitope tag may be, for example, AU5, c-Myc, CruzTag 09, CruzTag 22, CruzTag 41, Glu-Glu, HA, Ha.
- the fusion protein may be labeled so as to be a detectable protein.
- the detectable label may be a biotin Avi Tag of the biotin Z streptavidin type, a fluorescent substance, or the like.
- the fluorescent substance examples include a green jellyfish (Aequorea vie torea) and other luminescent jellyfish-derived threads ife fluorescent protein (green fluorescent protein). : GFP), mutants thereof (GFP variants) such as EGFP (Enhanced-hum anized GFP), rsGFP (red-shift GFP), yellow fluorescent protein (YFP), and fluorescent protein (green fluorescent protein: GFP), cyan fluorescent protein (CFP), Wfe fluorescent protein (BFP), and GFP derived from Reni lla reniformis. ⁇ Atsufumi Waki, Ed., Experimental Medicine Separate Volume, Experimental Lecture in the Post-Genome Era 3 -GFP and Nokuoi Iging, Yodosha (2000)).
- Detection can also be performed using an antibody (including a monoclonal antibody and a fragment thereof) that specifically recognizes the fusion tag.
- an antibody including a monoclonal antibody and a fragment thereof
- a suitably protected amino acid is sequentially bound to a desired amino acid sequence on the resin by various known condensation methods using, for example, a protein or peptide synthesizing element.
- condensation reaction the ability to use various activations known per se is preferred, and as such, for example, carposimids such as dicyclohexylcarposimid can be preferably used.
- a product power protecting group it is possible to obtain the desired product by removing the protecting group as appropriate. ,
- the protein can be prepared by a method known to those skilled in the art as a natural protein or as a recombinant protein prepared by using a recombinant technique.
- a natural protein is prepared by immunizing a small animal such as a mouse or a rabbit with the prepared recombinant protein and binding the antibody to an appropriate adsorbent (CNBr-activated agarose or tosyl-activated agarose).
- CNBr-activated agarose or tosyl-activated agarose an appropriate adsorbent
- Rikikawa is a method of preparing a column and using the resulting column to purify a protein extract of cells.
- the recombinant protein can be obtained by a conventional method, for example, by inserting a DNA encoding the protein into an appropriate expression vector, introducing the vector into an appropriate cell, and purifying from the transformed cell. It is powerfully possible to prepare.
- cells used for producing a recombinant protein include plant cells, animal cells such as Escherichia coli and yeast, animal cells, and insect cells.
- vectors for expressing a recombinant protein in cells include, for example, plasmids “pBI121” and “pBI101” (Clontech ⁇ ⁇ ⁇ t) for plants and yeast cells, and plasmids for E. coli.
- the transfer of the DNA to the vector can be performed by a conventional method, for example, the method described in Molecular Cloning (Maniatis et al., Cold Spring Harbor Laboratry Press).
- the introduction of the vector into the host cell can be carried out by a conventional method according to the host cell, such as an electrification method, a microinjection method, or a no-tickle gun method.
- Purification of the desired recombinant protein from the resulting transformed cells can be performed by salting out, precipitation with an organic solvent, ion exchange chromatography, affinity chromatography, or column chromatography using an immunoadsorbent, depending on the properties of the protein. , Gel filtration, SDS electrophoresis, isoelectric focusing, etc.
- the recombinant protein when expressed as a fusion protein with a label such as glutathione S-transferase, it can be purified by affinity chromatography or the like on the label.
- DNA encoding a protein or the like used in connection with control of p30-Rapl binding and binding angle is used.
- the DNA is not particularly limited as long as it can encode the desired protein according to the present invention, and includes genomic DNA, cDNA, DNA synthesized by DNA, and the like.
- Genomic DNA is obtained by using a genomic DM prepared according to a method known in the art as a ⁇ type and a primer prepared based on a predetermined DNA base sequence (for example, the base sequence described in FIG. 1). It can be prepared by performing polymerase chain reaction (PCR) using the enzyme.
- PCR polymerase chain reaction
- cDNA mRNA is prepared from cells by a conventional method (Maniatis et al. Molecular Cloning Cold Spring Harbor Laboratry Press), and reverse transcription is performed. 03 013937
- genomic DNA and cDNA a genomic DNA library or cDNA library is prepared by a conventional method, and this library is synthesized based on, for example, the base sequence of the DNA (eg, the base sequence shown in Figure 1). It can also be prepared by screening using the probe thus prepared.
- PCR generally refers to a method described in Saiki et al., Science, 239: 487 (1988); U.S. Pat. No. 4,683,195, for example, It refers to a method for enzymatically amplifying the desired nucleotide sequence at the mouth.
- PCR involves repeating two oligonucleotide primers capable of hybridizing preferentially to a type I nucleic acid, and repeating the cycle to perform a bramer-elongation synthesis.
- the primers used in the PCR method can: (1) use a primer that is complementary to the internal nucleotide sequence to be amplified; Both ends are preferably complementary to each other, or are capable of causing the nucleotide sequence to be amplified to preferably ffl.
- the primer at the end side should be selected so as to amplify at least the power containing the initiation codon, or the primer at the 3 'end side.
- the primer is preferably an oligonucleotide consisting of 5 or more bases, more preferably an oligonucleotide consisting of 10 or more bases, and more preferably an oligonucleotide consisting of 18 to 35 bases.
- PCR can be performed by a method known in the art or a method substantially similar to or a modification thereof.
- a method known in the art for example, in addition to the above-mentioned literature, R. Saiki, et al., Science, 230: 1350, 1985; HA Brlich ed., PCR Technology, Stockton Press, 1989; DM Glover et al. Ed., "DNA Cloning", 2nd ed., Vol. 1, (The Practica 1 Approach Series), IRL Press, Oxford Universi ty Press (1995); MA Inn is et al. ed., "PCR Protocols: a guide to methods and applications", Aca demic Press, New York (1990)); MJ McPherson, P.
- PCR can be performed using a commercially available kit suitable for the PCR, and can also be performed according to a protocol specified by a kit manufacturer or a kit distributor.
- PCR is typical; Ifi ⁇ include, for example ⁇ (for example, DNA was synthesized in ⁇ the mRNA; 1st strand DNA, etc.) and a primer one designed based on ⁇ 1, 10X reaction buffer (attached to Taq DNA polymerase), dNTPs (doxynucleoside triphosphate dATP, dGTP, dCTP, (mixture of ⁇ ), Taq DNA polymerase and deionized distilled water
- the cycle is repeated 25 to 60 times under general PCR cycle conditions using an automated thermal cycler, such as the GeneAmp 2400 PCR system, Perkin-Elmer / Cetus, for example.
- the number of cycles for PCR can be set to an appropriate number according to the purpose ..
- PCR cycle conditions include, for example, denaturation at 90 to 95 ° C for 5 to 100 seconds, and annealing at 40 to 60 ° C for 5 to 100 ° C. 150 sec, extension 65-75 ° C 30-300 sec cycle, preferably denaturing 94. C 15 , Annealing 58.C 15 seconds, elongation 72 ° C 45 seconds cycle power is strong, the reaction and time of the annealing can be selected appropriate value by perfect experiment, denaturation reaction and elongation The appropriate time can be selected according to the expected length of the PCR product.
- the ring reaction is usually changed according to the Tm value of the hybrid between the primer and type I DNA.
- the time for the extension reaction is generally about 1 minute per lOObp of chain length, but it is possible to select a shorter time with ⁇ .
- oligonucleotide is a relatively short strand, single strand or single strand. And preferably a polynucleotide. De O carboxymethyl nucleotides can be mentioned, Angew. C Hem. Int. Ed. Engl., Vol. 28, p. 716-734 (1989). Method, a phosphoramidite method, a phosphonate method and the like.
- synthesis is strongly known to be conveniently performed on a modified solid support, for example, using an automated synthesizer, which is commercially available.
- the oligonucleotide may or may contain a further modified, for example, it may contain an unnatural base such as inosine or a tritinolated base, or depending on the case. It may contain a strong base.
- hybridization techniques In order to identify a given nucleic acid, it is possible to use hybridization techniques. The hybridization can be carried out by the method described in the literature which discloses the above-mentioned "Genetic and Recombination Technology", or a method substantially similar to or a modification thereof.
- a sample containing nucleic acid such as DNA is transferred to a carrier including a membrane such as a nylon filter, and then subjected to denaturation treatment, immobilization treatment, washing treatment, etc., as necessary.
- the reaction is carried out by reacting the DNA transcribed on the carrier (for example, a membrane) with the denatured labeled probe DNA fragment, if necessary, in an amplification buffer.
- the hybridization process is usually performed at about 35 to about 80 ° C, more preferably about 50 to about 65, for about 15 minutes to about 36 hours, more preferably about 1 to about 24 hours. This can be done by selecting the optimal conditions. For example, the hybridization process is performed at about 55 ° C. for about 18 hours.
- the hybridization buffer can be selected from those commonly used in the field, and for example, a rapid hybridization buffer (Amersham) can be used.
- Examples of the denaturation treatment of the transferred carrier include a method of thinning an alkali denaturing solution. After the treatment, a treatment with a neutralizing solution or a buffer is preferable.
- the immobilization treatment of the carrier is usually performed at about 40 to about 100 ° C, more preferably about 70 to about 90 ° C, for about 15 minutes to about 24 hours, more preferably about It is possible to select the force and the child's condition by baking for 1 to about 4 hours.
- Phil Immobilization is carried out by baking a carrier such as a carrier at about 80 ° C for about 2 hours. Washing of the transferred carrier (eg, membrane) includes washing solutions commonly used in the art, such as 50 mM Tris-HC1 buffer containing 1 M NaCl, lmM EDTA, and 0.1% sodium dodecyl sulfate (SDS). , H8.0, etc. can be used for washing.
- a carrier including a membrane such as a nylon filter
- a carrier selected from those commonly used in this field can be used.
- alkali denaturing solution neutralizing solution and buffer solution
- examples of the alkali denaturing solution include 0.5M NaOH and 1.5M NaCl.
- examples of the neutralizing solution include a 1.5 M NaCl-containing 0.5 M Tris-HCl buffer, H8.0, and the like.
- Examples of the buffer include XSSPE (0. 36M NaCU 20mM NaH 2 P0 4 and 2 ⁇ M EDTA) may Ku force possible and the like.
- the transferred carrier for example, a membrane or the like
- a prehybridization treatment is performed, for example, in a pre-hybridization overnight [50% formamide.
- Power to do The hybridization can be carried out by a method known per se or a method analogous thereto.
- the stringent condition in the present specification is, for example, about 15 to about 50 mM, preferably with respect to sodium concentration. Is about 19 to about 40, more preferably about 19 to about 20 mM, for about 35 to about 85 ° C, preferably about 50 to about 70 ° C, more preferably about 60 to about 65 ° C. Show.
- the detection process can be strengthened.
- the washing treatment of the carrier such as a filter can be carried out by selecting and using those commonly used in the art.For example, 0.5 XSSC containing 0.1% SDS (0.15M NaCl, Acid) It can be carried out by washing at night.
- the hybridized nucleic acid can be typically detected by autoradiography, but it can also be used for detection by selecting from the methods used in this field.
- nucleic acid bands corresponding to the detected signal a suitable buffer, if example embodiment, SM solution (lOOmM NaCl and 10 mM MgSO 4 containing 50 mM Tris-HCl buffer, H7. 5) was suspended in like, then the suspension After appropriate dilution, the desired nucleic acid can be isolated, purified, and subjected to further processing.
- SM solution lOOmM NaCl and 10 mM MgSO 4 containing 50 mM Tris-HCl buffer, H7. 5
- a cloned human-derived cDNA library for example, various human-derived paper woven or cultured cells (particularly, human kidney, brain, pineal gland, posterior pituitary gland, god of the sun, retina, Reticulum cells, retinal sinusoids, thymus, blood vessels, endothelial cells, vascular smooth muscle cells, blood cells, macrophages, lymphocytes, testes, ovaries, ova, intestine, heart, liver, kidney, small intestine , Large intestine, gingival-related cells, skin-related cells, glomerular cells, tubule cells, connective filament cells, etc., and various types of UK thread!
- a commercially available cDNA library derived from various yarns and fibers can be used directly.
- a cDNA library commercially available from Stratagene, Invrogen, Clontech, etc. You can use force.
- a typical example is a gene library prepared from human thread cells, such as a human PI artificial chromosome genomic library (Human Genome Mapping Resource Center) ⁇ a human tissue cDNA library (for example, from Clontech). (Available).
- a human genomic DNA library or a human-derived cDNA library constructed from various human tissues or cultured cells can be screened with a probe.
- a commercially available labeling kit for example, a random prime DNA labeling kit (Boehringer Mannheim) can be used.
- Random- priming kit Pharmacia LKB, Inc., UPPS ala
- DNA probe [- 3 2 P] dCTP Amersham Corp. was-labeled, etc., to obtain the probes with radioactive it can.
- Phage particles, recombinant plasmids, ligated vectors, etc., which carry the nucleic acid of the standard J, can be purified and separated by methods commonly used in the art. Purification can be carried out by an ultracentrifugal separation method (Molecular Cloning, a laboratory manual, ed. T. Maniatis, Cold Spring Harbor Laboratory, 2nd ed. 78, 1989), electrophoresis, or the like. Such as from phage particles, it is possible to purify separating DNA in a way that is commonly used in the art, for example, resulting phage TM sickle (10 mM MgSO 4 containing 50 mM Tris -.
- the target DNA can also be obtained by subcloning or the like. For example, subcloning can be carried out using a bacterium as a host and a plasmid vector.
- the DNA obtained by such subcloning can be purified and separated by methods such as centrifugation, phenol extraction, and ethanol precipitation in the same manner as described above.
- the force depending on the length of the age target sequence such as “high homology” is, for example, 50% or more, further 60% or more, preferably 70% or more, more preferably 80% or more, and specific. It may be at least 95%, particularly preferably at least 97%.
- the “equivalent nucleotide sequence” may be, for example, one that hybridizes with a sequence having a problem under stringent conditions.
- nucleic acids can also be obtained by DNA synthesis. The fragments may be chemically synthesized and linked together by enzymes. In the present specification, the obtained nucleic acid (including DNA) such as a PCR product is usually subjected to 1 to agarose gel electrophoresis, cut out from the gel as a specific band, for example, ene clean kit (Bio 101) or the like. Extract using a commercially available extraction kit.
- the extracted DNA is cleaved with an appropriate restriction enzyme, purified if necessary, and further, if necessary, phosphorylated at the 5 'end with T4 polynucleotide kinase or the like, and then pUC vector such as pUC18. Ligate to a suitable plasmid vector, such as one, and transform a suitable competent cell.
- p-Direct C1 ontech
- pCR-Script TM SK (+) (Stratagene)
- GEM-T Promega
- pAmp TM Gibco-BRL
- a commercially available plasmid vector can be used.
- phage vector For transformation of host cells, for example, use of phage vector, calcium method, rubidium / calcium method, calcium / manganese method, high-efficiency TFB, FSB freezing cell method, rapid colony method
- the method can be performed by a method known in the art such as electroporation or a method substantially similar thereto (D. Hanahan, J. Mol. Biol., 166: 557, 1983, etc.).
- 3 ⁇ 4ife- ⁇ PCR polymerase chain reaction coupled reverse transcription; RT-PCR
- RACE rapid amplification of cDNA ends
- MCE is described in, for example, M, A. Innis et al. Ed., "PCR Protocols" (MA Frohman, "a guide to methods and applications"), pp. 28-38, Academic Press, New York (1990). And the like.
- the DNA can be cloned as required, and for example, plasmid, sphage, cosmid, P1 phage, F factor, YAC and the like can be used.
- sphage For example, Charon 4A, Charon 21A, AgtlO, gtl DASHI K S FIXI I, A EMBL3, ⁇ ⁇ ⁇ TM (Stratagene) and the like can be used.
- the obtained DNA is transformed into a suitable vector as described in detail below, for example, a vector such as plasmid pEX, pMAMneo, pKG5, etc., into a suitable host as described in detail below.
- Cells for example, E.
- the DNA fragment may be used as it is or as a DNA fragment to which an appropriate control sequence has been added, or may be inserted into an appropriate vector, and then introduced into an animal to express a transgene expressing a predetermined gene.
- a transgenic animal can be prepared by introducing the DNA fragment into a fertilized egg of an animal such as a mouse.
- the confirmation of the predetermined gene product can be carried out using an animal packet suitable for the transfection of the gene, such as 293T cells and COS-1 cells.
- a method for introducing a gene into an animal cell such as a mammal can be carried out by a method known in the art or a method substantially similar thereto.
- the cane phosphate method for example, FL Graham et al.) al., Virology, 52: 456, 1973
- DEAE-dextran method eg, D. Warden et al., J. Gen. Virol., 3: 371, 1968
- electroporation method eg, E. Neumann et al., ⁇ J, 1: 841, 1982
- microinjection method eg, ribosome method, virus infection method, phage particle method, and the like.
- plasmids there are 5 types of host cells commonly used in engineering (eg, prokaryotic host cells such as E. coli, Bacillus subtilis, etc., eukaryotic host cells such as yeast, 293T cell, CH0 cell, COS cell, etc. Any plasmid that can express the DNA force in insect cell host such as Sf21 may be used.
- prokaryotic host cells such as E. coli, Bacillus subtilis, etc.
- eukaryotic host cells such as yeast, 293T cell, CH0 cell, COS cell, etc.
- Any plasmid that can express the DNA force in insect cell host such as Sf21 may be used.
- a modified gene suitable for expression in the selected host It can contain a codon force, a restriction enzyme site can be provided, and control sequences and facilitating sequences for facilitating the expression of the target gene.
- Sequences useful for binding such as linkers and adapters, as well as controlling material resistance, metabolism, and selection (including those encoding hybrid proteins and fusion proteins) ) It can be powerful.
- an appropriate promoter for example, a plasmid using Escherichia coli as a host, includes tryptophan promoter (trp), lactose promoter (lac), tryptophan 'lactose promoter (tac), lipoprotein promoter (lpp). ), the Sufaji P L promoter, First, the bra Sumi de an animal cell is used as the host, SV40 late promoter, MMTV LTR promoter, RSV LTR promoter one coater, CMV promoter mono-, the SRa promoter, the yeast as a host plasmid For example, the GALK GAL10 promoter may be used.
- control systems such as CYC1, HIS3, ADH1, PGK, PH05, GAPDH, ADC1, TRP1, URA3, LEU2, ENO, TP1, and A0X1 can also be used.
- An enhancer can be inserted into the vector to promote transcription of the DNA encoding the desired polypeptide, and such enhancers act on the motor to promote transcription. Elements having a cis action of usually about 10 to 100 bp. It is known from many mammalian genes such as Enhansa globin, elastase, albumin, a-fetoprotein, and insulin.
- cell-infectious viruses such as SV40 enhancer (100-270 bp) in the rate region of the replication origin, and the enhancer of the early cytomegalovirus promoter. 1, Enhansa in the late shell of the polio replication origin, Enhansa of the adenovirus, and the like. If necessary, a signal rooster B ⁇ ij suitable for the host can be added, and these can be those well known to those skilled in the art.
- Plasmid vectors suitable for expression in E. coli include, for example, pAS, pI (K223 (Pharmacia), pMC1403, pMC931, pKC30, pRSET-B (Invitrogen), etc.
- Plasmids include, for example, SV40 vector, poliovirus, virus vector, vaccinia virus vector, retrovirus vector, etc. Specifically, pcD, pcD-SRa, CDM8, pCBV4, pB18S, PBC12BI, pSG5 (Stratagene), etc. Examples of plasmids using yeast as a host include Yip type vector, YEp type vector, YRp type vector, YCp type vector, and the like. For example, pGPD-2, etc.
- Examples of the host cell include those derived from a bacterium of which the host cell is a free bacterium, for example, a strain derived from the K12 strain, for example, 533, XL1-Blue, C600, DH1, DH5, DH11S, DH12S, DH5, DH10B, thigh 01, MC1061, JM109, STBL2, B834
- Examples of strain origin include BL21 (DE3) pLysS etc.
- Yado Soda is a yeast 3 ⁇ 4.
- Inner cells ⁇ 1 spores are i ⁇ ⁇ of animal cells, such as COS-7 cells, COS-1 cells, CV-1 cells derived from African green monkey fibroblasts, and human kidney cells 293 Cells, human cell lines * A4 31 cells, human colon-derived 205 cells, mouse blastoma-derived COP cells, MOP cells, W0P cells, Chinese hamster cell-derived CH0 cells, CH0 DHFR-cells, and human HeLa Cells, C127 cells derived from mouse cells, NIH 3T3 cells derived from mouse cells, mouse L cells, 9BHK, HL-60, U937, HaK, Jurkat cells, other transformed cell lines, normal diploid cells Invito mouth is derived from primary culture paper weave Cell strains and the like.
- animal cells such as COS-7 cells, COS-1 cells, CV-1 cells derived from African green monkey fibroblasts, and human kidney cells 293 Cells, human cell lines * A4 31 cells, human colon-derived 205 cells, mouse blastoma-derived
- Insect cells include Bombyx mori nuclear polyhedrosis virus and its derivatives or other appropriate ones, and Spodoptera frugiperda (caterpi l lar), Aedes aegyp ti (mosqui to) , Aedes albopictus (mosqui to), Drosophi la melangaster (frui tf ly), silkworm larvae or cultured silkworm cells, such as BM-N cells (Eg, Luckow et al, Bio / Technology, 6, 47-55 (1988); Setlow, JK et al. (Eds.), Genetic Engineering, Vol. 8, pp.
- Restriction enzymes include, for example, RJ Roberts, Nucleic Acids Res., 13: rl65, 1985; S. Linn et al. Ed. Nucleases, p. 109, Cold Spring Harbor Lab., Cold Spring Harbor, New York, 1982.
- RJ Roberts, D. Mace is, Nucleic Acids Res., 19: Suppl. 2077, 1991 and the like.
- a transformant transformed with an expression vector containing a nucleic acid encoding a polypeptide (or protein) can be repeatedly cloned using an appropriate selection marker if necessary. Therefore, it is possible to obtain a cell line stably having a high expression ability.
- the dhfr preference was used as a selection marker, and cultivation was carried out by gradually increasing the TX concentration to select a resistant strain. Amplifying the DM encoding the polypeptide of the present invention, and obtaining a cell line that can obtain higher expression.
- the transformant of the present invention can be cultured under conditions in which a nucleic acid encoding the polypeptide of the present invention can be expressed to produce and accumulate the desired product.
- the transformant can be cultured in a medium commonly used in this field.
- a transformant using a prokaryotic host such as Escherichia coli or Bacillus subtilis, or a yeast as a host can suitably use a liquid medium.
- the medium contains a carbon source, a nitrogen source, no shelves and others necessary for the growth of the transformant.
- carbon sources include glucose, dextrin, soluble starch, and sucrose.
- nitrogen sources include ammonium salts, nitric acid: ⁇ , corn chip liqueur, peptone, casein, meat extract, and malt.
- Inorganic or fragile substances such as extracts, soybean meal, potato extract, etc., include, for example, canolesum chloride, sodium dihydrogen phosphate, magnesium chloride, calcium carbonate and the like.
- yeast vitamins, casamino acids, growth promoting factors and the like may be added.
- a drug such as 3 / 3-indolinoleacrinoleic acid can be added to make the promoter work efficiently.
- the pH of the ground is about 5 to about 8 force.
- cultivation of Escherichia coli is usually carried out at about 15 to about 45 ° C for about 3 to about 75 hours, and if necessary, aeration and stirring can be applied.
- a MEM medium containing about 5 to about 20% fetal bovine serum, PR1640 ⁇ ground, DMEM medium and the like are used as a medium.
- the pH is from about 6 to about 8.
- Culture is usually performed at about 30 to about 40 ° C for about 15 to about 72 hours. Aeration and stirring are added as necessary.
- Transformants that express a given product can be used as they are, but they can also be used as their cell homogenates, but a given gene product can be isolated and used.
- the cells or cells are collected by known methods after culture, suspended in an appropriate buffer, and sonicated, lysozyme and / or freeze-thaw, etc. After the cells are destroyed, a method of obtaining a crude extract by centrifugation or filtration can be used.
- Some buffers include protein denaturants such as urea and guanidine hydrochloride, and Triton X-100 (trade name).
- Surfactants such as Zwien-20 (trade name) may be added.
- the supernatant is separated from the cells or cells by a method known per se, and the supernatant is collected.
- the target substance contained in the culture supernatant or extract obtained in this manner can be purified by appropriately combining known separation and purification methods, such as the ammonium sulfate precipitation method.
- Salt filtration gel filtration by Sephadex, etc., for example, a methylaminoethyl group, ion exchange chromatography using a carrier having a carboxymethyl group, etc., for example, butyl group, octyl group, A carrier with hydrophobic 3 ⁇ 4S such as phenyl group is used.
- purification and separation can be carried out by polyacrylamide gel electrophoresis, affinity 1 'chromatography with immobilized ligands and the like.
- gelatin-agarose-affinity chromatography, heparin-agarose-chromatography and the like can be mentioned.
- the resulting protein (including peptides or polypeptides) is then immobilized by binding it to a suitable carrier or solid phase by known methods such as enzyme immunoassay. You can be powerful.
- the solid-phased protein and solid-phased peptide can be conveniently used for screening of binding substances.
- the related proteins disclosed herein, fragments thereof, and nucleic acids (including mRNA oligonucleotides), including DNA can also be used in reticulum or organically, and further using antisense technology, It can be applied to genomics and proteomics technology in combination with antibodies, including monoclonal antibodies, and transgenic animals.
- RNAi RNA interference
- dsRNA strand RNA
- SNPs single nucleotide polymorphisms
- protein arrays 3 ⁇ 4Existing rice cake loaf, relic 5? Functional analysis, protein-protein interaction analysis, related gene ! It becomes possible to make a loaf.
- a cDNA library is used, or the DNA obtained by the PCR technology is placed at a high density using a spotting device based on the DNA obtained by the PCR technology, and the sample is analyzed using a hybridization.
- the arraying is performed by using a needle or a pin, or by using an ink jet printing technique or the like, by attaching DNA to a unique position on a substrate such as a slide glass, a silicon plate, or a plastic plate with a strong force of DNA. I can do it.
- Data is obtained by observing a signal obtained as a result of hybridization on the nucleic acid array.
- the signal is a label such as a fluorescent dye (eg, For example, it may be obtained from Cy3, Cy5, BODIPY, FITC, Alexa Fluor dyes (trade name), Texas red (trade name), etc.
- a laser-scanner may be used for the detection, and the obtained data may be processed by a computer system equipped with a program according to an appropriate algorithm.
- the protein array technology may utilize tagged recombinant expressed protein products, such as two-dimensional electrophoresis (2-DE), mass spectrometry (MS) including enzyme digestion fragments (MS) ( This includes techniques such as electrospray ionization (ESI), matrix-assisted laser desorption / ionization (MALDI), and other techniques such as MALDI-T0F analyzers.
- ESI electrospray ionization
- MALDI matrix-assisted laser desorption / ionization
- MALDI-T0F analyzers such as MALDI-T0F analyzers.
- ESI triple quadrupole analyzer, ES toion trap analyzer, etc. may be used), staining technology, isotope labeling and analysis, image processing technology, etc. can be used. Therefore, the present invention may include the above-described p30 and its related analogs, and the like, and software and databases related to antibodies thereto.
- a predetermined DNA for example, DNA encoding p30 or Rapl
- it is generally used as a DNA fragment or by binding the DNA downstream of a promoter capable of expressing the DNA in animal cells.
- the DNA is introduced into a mouse: ⁇ , a gene construct linked to the downstream of one of various promoters capable of expressing the DNA derived from an animal having a high homology to animal cells in a fertilized egg of a target animal, for example.
- the mouse is not particularly limited to a pure mouse, for example, C57BL / 6, Balb / C, C3H, (BDF,) and the like.
- a promoter for example, a virus-derived promoter, a ubiquitous expression promoter such as metamouth thionein, or the like can be preferably used.
- the DNA is introduced: ⁇ , the recombinant fermentation can be carried out using the recombinant retrovirus.
- ⁇ Preferably, the mouse fertilized egg into which the human DNA has been introduced may be, for example, a foster mouse such as ICR. It can be used to grow.
- the DNA at the fertilized egg cell stage (for example, DN encoding p30 or Rapl)
- the metastasis of A) is ensured to be present in all germ cells and somatic cells of the target animal.
- the presence of DNA power that encodes the protein in the germinal cells of the produced animal after DNA transfer means that the offspring of the produced animal have DNA encoding the protein in all of its germ cells and somatic cells. means. Progeny of such animals that have inherited the gene have the potential to express the protein in all of their germinal and somatic cells. After confirming that the DNA-transferred animal stably retains the gene by mating, the animal can be reared in a normal breeding environment as the DNA-bearing animal.
- Homozygous animals having the transfected fei on both homologous chromosomes are obtained by breeding male animals, and all are bred by breeding this fiber animal. Offspring can be propagated to carry the DNA.
- the animal guided by the DNA has high expression of the protein and is useful as an animal for screening (inhibitor) against the protein and the protein. Further, it is useful as an antisense oligonucleotide capable of inhibiting the expression of the gene, for example, an animal for screening antisense DNA or the like.
- the transgenic animal can also be used as a cell source for tissue culture.
- ⁇ 30 Cells of the fiber producing the protein are cultured by standard tissue culture techniques, and these cells are used to produce, for example, vascular cells such as brain, thymus, intravascular cells, blood cells, testis, brain, intestine, kidney and others. Thread! ⁇ Functions of cells derived from tissue can be studied. By using the cells, it is also possible to contribute to the development of a drug that enhances the functions of various tissues, for example. If there is a high expression cell line, the protein can be isolated and purified therefrom.
- antibody may be used in a broad sense, and may be a monoclonal antibody against the P30 protein, its constituent polypeptides and related peptide fragments as desired by Toji J A single antibody or an antibody composition having specificity for various epitopes, and further includes a monovalent antibody or a multivalent antibody, and a polyclonal antibody and a monoclonal antibody. It also refers to native (intact) molecules and fragments and fragments thereof, including fragments such as F (ab ') 2 , Fab' and Fab, plus at least two antigens or epitopes.
- Chimeric or hybrid antibodies having the ⁇ position, or bispecific recombinant antibodies such as, for example, quadromes and triomes, interspecific hybrid antibodies, anti-idiotypic antibodies
- Antibodies obtained using the conventional techniques known in the art such as antibodies obtained using antibodies, or antibodies prepared using DNA recombination techniques, target antigenic substances or target epitopes as described and defined herein. For example, antibodies that have neutralizing properties or antibodies that have binding properties may be included.
- Particularly preferred antibodies of the present invention include those capable of specifically modulating a polypeptide selected from the N-terminal region of P30.
- Monoclonal antibodies produced against the antigenic substance can be produced using any method that allows the production of antibody molecules to be controlled by a series of cell lines during culture. Shushoku Go Monoclonal refers to the character of a lie antibody when it is obtained from a substantially homogeneous population of antibodies, and the antibody must be produced by any specific method. Do not assume that there is.
- Each monoclonal antibody contains a population of antibodies that are identical except that there may be small amounts of variants that may occur naturally.
- Monochrome nanore Antibodies are highly specific, being directed against a single antigenic site.
- each monoclonal antibody In contrast to a conventional (polyclonal) antibody preparation, which typically contains a variety of antibodies directed against different antigenic determinants (epitopes), each monoclonal antibody is It is directed against a single antigenic determinant on the original. In addition to their specificity, monoclonal antibodies are also excellent in that they are synthesized by fermentation, and are free or low in 3-1 of other immunoglobulins. Monoclonal antibodies include hybrid antibodies and recombinant antibodies. They replace the variable region domain with a constant region domain, replace the light chain with a heavy chain, or replace certain chains, regardless of their origin or immunoglobulin class I subclass, as long as they exhibit the desired biological activity.
- Suitable methods for producing monoclonal antibodies include the hybridoma method (G. Kohler and C. Milstein, Nature, 256, pp. 95-497 (1975)); the human B cell hybridoma method (Kozbor et al. al., Immunology Today, 4, pp. 72-79 (1983); Kozbor,
- antibodies derived from the species A force that is the same or homologous to the corresponding sequence of the antibody belonging to the class or subclass, while the remainder of the chain corresponds to the corresponding sequence of the antibody derived from another species or belonging to another antibody class or subclass.
- the monoclonal antibody of the present invention can be used for cell fusion techniques using myeoma cells (eg, G. Kohler and C. Milstein, Nature, 256, pp. 495-497 (1975)).
- the antibody may be a monoclonal antibody obtained by using the following method. For example, it can be produced by the following steps.
- the ability to use the isolated P30 polypeptide or a fragment derived therefrom can be used.
- the determined amino acid sequence of the p30 protein can be used as the antigen. Based on this, it is possible to chemically synthesize appropriate oligopeptides and use them as antigens.
- a peptide having at least five intermittent amino acids among the amino acid residues present in FIG. 1 is mentioned. For example, selecting an appropriate portion from a specific sequence, for example, an amino acid sequence on the terminal side or the like can be mentioned.
- the antigen may be used in the form of a strong conjugate which can be used to immunize animals by mixing it with an appropriate adjuvant as it is;
- the antigen used as the immunogen is a fragment obtained by fragmenting the protein, or a characteristic sequence region selected based on the amino acid sequence, and a synthetic polypeptide obtained by designing and chemically synthesizing the polypeptide. It may be a fragment.
- the fragment can be bound to various carrier proteins via an appropriate condensing agent to form an immunogenic conjugant such as peptide protein, which can be used to react with only a specific sequence. It can also be used to design monoclonal antibodies (or recognize only specific sequences).
- a cysteine residue or the like can be added to the polypeptide to be designed in advance so that the immunogenic conjugate can be prepared at a reasonable price.
- the carrier proteins Upon binding to carrier proteins, the carrier proteins can first be activated.
- the ability to introduce an activating linking group in such activation is mentioned.
- the activated linking group include (1) an activated ester or an activated carboxyl group, for example, a nitrophenyl ester group, a pentafluorophenyl ester group, a tribenzotriazole ester group, an N-succinimide ester group, (2)
- An activated dithio group for example, a 2-pyridyldithio group.
- carrier proteins include keyhole 'limpet' hemocyanin (KLH :), bovine serum albumin (BSA), ovalbumin, polypeptides such as glopurine and polylysine, and bacterial cell components such as BCG.
- KLH keyhole 'limpet' hemocyanin
- BSA bovine serum albumin
- ovalbumin polypeptides such as glopurine and polylysine
- bacterial cell components such as BCG.
- Immunization can be performed by methods known to those skilled in the art. For example, Shigeru Muramatsu, et al., Experimental Biology ⁇ ! Maru 14, Immunology, Maruzen Co., Ltd., 1985, Ed. Experimental Lecture 5 ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇
- the immunizing agent and the adjuvant or adjuvant are administered to a mammal multiple times by subcutaneous thigh or intracavity incision.
- the immunizing agent include those containing the above antigen peptide or its related peptide fragment.
- the immunizing agent is a protein known to be immune in the mammal being immunized
- adjuvants include Freund's complete adjuvant, Ribi adjuvant, pertussis vaccine, BCG, Lipid KA, Liposomal, aluminum hydroxide, silica, and the like. Immunization is performed using mice, such as BALB / c, hamsters, or other suitable animals.
- the dose of the antigen is, for example, about 1 to about 400 ⁇ g / animal for the mouse, which is generally measured in the host animal's shiki or subcutaneously, and thereafter every 1 to 4 weeks, preferably 1 to 2 Booster immunizations are performed 2 to 10 times weekly, subcutaneously, subcutaneously, intravenously or intramuscularly.
- the immunizing mouse may be a BALB / c mouse or an F1 mouse of a BALB / c mouse and another mouse. If necessary, an antibody titer can be prepared and the antibody titer can be measured to confirm the animal immunity.
- the antibody of the present invention may be obtained from the immunized animal obtained as described above, and includes, for example, purified antibodies, polyclonal antibodies, and the like.
- the infinitely proliferative strain (® ⁇ cell strain) used for cell fusion can be selected from cell lines that do not produce immunoglobulin.
- P3-NS-1-Ag4-1 NS-1, Eur. J. Immunol., 6: 511-519, 1976
- SP-2 / 0-Agl4 SP-2, Nature, 276: 269-270, 1978
- P3-X63-Ag8 derived from mouse myeloma MOPC-21 cell line -Ul (P3U1, C urr. topics Microbiol.
- the 8-azaguanine-resistant mouse myeloma cell line is prepared by adding a substance such as penicillin or amikacin, fetal calf serum (FCS), etc. to cells such as Dulbecco's MEM ⁇ medium (DMEM medium) and RPMI-1640 medium.
- An animal for example, a mouse immunized according to the above step 2 is excised from 2 to 5 days after the final immunization, and then a spleen cell suspension is obtained.
- lymph node cells from various parts of the body can be obtained and used for cell fusion.
- the thus obtained spleen cell suspension and the myeloma cell line obtained according to the above step 3 are placed in a cell medium such as a minimum essential medium (MEM ⁇ : 1), DMEM medium, RPMI-1640 medium and the like.
- a cell fusion agent such as polyethylene glycol is added. Other cell fusion agents known in the art can be used.
- cell fusion agents include inactivated Sendai virus (HVJ: Hemagglutinating Virus of Japan).
- HVJ Hemagglutinating Virus of Japan
- 0.5 to 2 ml of, for example, 30 to 60% of polyethylene glycol can be added, and polyethylene glycol having a molecular weight of 1,000 to 8,000 can be used strongly. 4,000 polyethylene glycols are more preferred.
- concentration of polyethylene glycol in the fusion medium be, for example, 30-60%.
- a small amount of dimethyl sulfoxide for example, can be used to promote fusion.
- the ratio of spleen cells (lymphocytes) to be transformed into a myeloma cell line is, for example, from 1: 1 to 20: 1. ⁇ Forced force, more preferably 4: 1 to 7: 1. "it can.
- the selection medium examples include a medium such as MEM medium containing FCS and RPMI-1640 medium containing hypoxanthine, aminopterin and thymidine, so-called HAT ⁇ medium.
- the method of replacing the selective medium is generally the same as the volume dispensed to the culture plate, added to the next day, and then replaced every half day in HAT ⁇ ground every 1 to 3 days. «: This can be done with some modifications.
- the aminopterin is removed, and the medium can be replaced with a so-called HT medium every 1 to 4 days.
- a feeder for example, mouse thymocytes may be used, which is preferred: ⁇ .
- the ability of the hybridoma to grow and the culture supernatant of the culture medium can be analyzed using a measurement system such as radioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA), or fluorescent immunoassay (FIA), or a fluorescence-inducing cell assay.
- a measurement system such as radioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA), or fluorescent immunoassay (FIA), or a fluorescence-inducing cell assay.
- Screening is performed by using a predetermined fragment peptide as an antigen with a Philips device (FACS) or the like, or by measuring a target antibody using a labeled anti-mouse antibody.
- Cloning can be achieved by the ability to pick up colonies in an agar medium, or by limiting dilution. It can be performed more preferably by the limiting dilution method. Cloning can be performed multiple times.
- the obtained hybridoma strain is cultured in an appropriate growth medium such as MEM medium containing FCS or RPMI-1640 ⁇ ground, and the culture medium is used to obtain the desired monoclonal antibody from the culture medium. I can do it.
- an appropriate growth medium such as MEM medium containing FCS or RPMI-1640 ⁇ ground
- the culture medium is used to obtain the desired monoclonal antibody from the culture medium. I can do it.
- Each hybridoma is transplanted into the transmigration of an animal derived from the myeoma cell line and / or a tissue-compatible animal. Transplanted, allowed to sprout, and produced in 13 ⁇ 41 ascites It can be obtained by collecting oral antibodies.
- the animal can administer a mineral oil such as pristane (2,6,10,14-tetramethylpentadecane) into the airplane.
- the ascites fluid may be used as it is or by a conventionally known method, for example, salt filtration such as ammonium sulfate precipitation, gel filtration using Sephadex, etc., ion exchange chromatography, electrophoresis, dialysis, ultrafiltration, It can be purified by T-chromatography and high-performance liquid chromatography and used as a monoclonal antibody.
- the ascites containing the monoclonal antibody can be purified and separated by fractionating with ammonium sulfate and then treating it with an anion exchange gel such as DEAE-Sepharose and an affinity column such as a protein column.
- affinity chromatography in which an antigen or an antigen fragment (eg, a synthetic peptide, a recombinant antigen protein or peptide, a site specifically recognized by an antibody) is immobilized, and protein A is immobilized.
- an antigen or an antigen fragment eg, a synthetic peptide, a recombinant antigen protein or peptide, a site specifically recognized by an antibody
- protein A is immobilized.
- transgenic mice or other organisms such as other mammals, can be used to express antibodies, such as humanized antibodies, to the immunized polypeptide products of the present invention.
- nucleic acid sequence encoding an antibody obtained from a hybridoma strain is isolated by a conventional method, for example, using an oligonucleotide probe capable of specifically binding to the heavy chain of a mouse antibody or a gene encoding a light chain. (J can be determined. Once isolated, the DNA is put into an expression vector as described above, and CH0,
- the DNA can be placed in a host cell such as COS.
- the DNA can be modified by, for example, substituting a human heavy or light chain constant region domain with a coding sequence instead of a homogenous mouse sequence (Morrison et al. , Proc. Natl.
- Antibodies can also be modified, such as by preparing chimeric or hybrid antibodies, by applying chemical protein synthesis, including the use of the following condensing agents. Humanized antibodies are capable of being performed using techniques known in the art (eg,
- Human monoclonal antibodies can also be obtained by techniques known in the art.Human myeloma cells / human / mouse heteromyeloma cells for producing human monoclonal antibodies are known in the art. (Kozbor, J. Immunol., 133, pp. 3001 (1984); Brodeur et al., Monoclonal Antibody Production Technologies and Applications, pp.
- Antibodies can be tested in any of the known methods, such as competitive binding assays, direct and indirect sandwich assays, and immunoprecipitation (Zola, Monoclonal Antibodies: A Manual of Techniques, pp). 147-158 (CRC Press, Inc., 1987) Any method known in the art can be used to conjugate antibodies to detectable groups, for example, David et al. , Biochemistry, 13, 1014-1021 (1974); Pain et al, J. Immunol. Meth., 40: pp. 219-231 (1981); and "Methods in Enzymology", Vol. 184 pp. 138-. 163 (1990), etc.
- an IgG fraction As the antibody to be labeled, an IgG fraction, and further, specific binding ⁇ Fab 'obtained by reducing after reducing pepsin are used.
- these 3 ⁇ 4 ⁇ labeled substances include enzymes (peroxidase, alkali) Phosphatases or yS-D-galactosidases), diagenetic substances, fluorescent substances, and radioisotopes.
- Detection and measurement in the present invention can be carried out by immunostaining, for example, fiber staining, cell staining, atsay, for example, competitive or noncompetitive immunoassay, and radioimmunoassay, ELISA, etc. Can be used to perform the BF separation or to perform the measurement without it.
- a radioimmunoassay and an enzyme immunoassay and further include a sandwich type assay.
- sandwich-type assay one is an antibody against the protein of the present invention and its related peptide fragment, the is an antibody against the N-terminal residue of the protein, and the other is detectably labeled.
- Another antibody that can recognize the same antigen is immobilized on the solid phase. Incubate the sample to allow the labeled antibody and solid-phased antibody to react sequentially if necessary. Separate the unbound antibody here and measure the label. The amount of label measured is proportional to the amount of antigen, ie, the polypeptide fragment antigen.
- this assay it is called a simultaneous sandwich type assay, a forward sandwich type assay, or a reverse sandwich type assay according to the order of addition of an insolubilized antibody or a labeled antibody. For example, washing, shaking, shaking, filtration, or pre-extraction of antigens, etc. are used in these procedures under certain circumstances.
- Other measurements such as the specific concentration of the buffer, the concentration of the buffer solution, or the incubation time, can be varied according to factors such as the concentration of the antigen in the sample and the properties of the sample.
- Many carriers capable of immobilizing an antigen or antibody are known, and in the present invention, they can be appropriately selected and used therefrom.
- the carrier various types of carriers which are ⁇ M in the antibody reaction or the like are known, and in the present invention, of course, those known ones can be selected and used. Particularly preferably used are, for example, glass, for example, inorganic materials such as active glass, porous glass, silica gel, silica mono-alumina, alumina, magnetized iron, and magnetic alloy, polyethylene, polypropylene, and poly.
- glass for example, inorganic materials such as active glass, porous glass, silica gel, silica mono-alumina, alumina, magnetized iron, and magnetic alloy, polyethylene, polypropylene, and poly.
- PVC Nyl polyvinylidene fluoride, polyvinyl acetate, polymethacrylate, polystyrene styrene-butadiene copolymer, polyacrylamide, cross-linked polyacrylamide, styrene-methacrylate copolymer, polyglycidyl methacrylate, acrolein-ethylene glycol Mono- or methacrylate copolymers, such as cross-linked albumin, collagen, gelatin, dextran, lygarose, cross-linked agarose, cellulose, microcrystalline cellulose, carboxymethyl cellulose, cellulose acetate, etc., natural or denatured cellulose, cross-linked dextran, nylon, etc.
- High quality organic materials such as polyamides, polyurethanes and polyepoxy resins, and those obtained by emulsion polymerization of them, cells, erythrocytes, etc. Like force that are introduced with a functional group in such coupling agents.
- filter paper, beads, the inner wall of the test container for example, test tubes, cells made of synthetic materials such as titer plates, titer cells, glass cells, synthetic resin cells, glass rods, rods made of synthetic material, and ends
- a solid material such as a stick that is thickened or thinned, a stick with a round or projection at its end, or a stick with a flat projection, or a stick that is shaped like an acknowledgment.
- An antibody can be bound to these carriers, and preferably, a monoclonal antibody that specifically reacts with the antibody obtained in the present invention can be bound thereto.
- the binding between the carrier and those involved in the antigen-antibody reaction can be performed by physical methods such as adsorption, chemical methods using a condensing agent, activated substances, or the like. It can be performed by a method that uses the chemical bonding reaction of
- Labels include enzymes, enzyme substrates, enzyme inhibitors, prostheses, coenzymes, enzyme precursors, apoenzymes, fluorescent substances, coloring substances, chemiluminescent compounds, luminescent substances, coloring substances, magnetic substances, metal particles, for example. Radioactive materials such as gold colloid can be mentioned.
- enzymes include oxidoreductases such as SfeK enzyme, reductase, and oxidase.
- Yoshii a hydrolytic enzyme that hydrolyzes glycoside bonds, ether bonds, peptide bonds, etc., lyase, iso Melase, ligase, etc. can be mentioned.
- the enzyme can be used for detection by using a plurality of enzymes in combination. For example, you can use a modest cycling.
- the standard ⁇ ) 3 ⁇ 4 isotopes typical person M dimensions substance, [3 2 ⁇ ], [ 1 2 5 ⁇ ], [1 3, ⁇ ],
- Representative enzyme labels include peroxidases such as horseradish peroxidase.
- -Galactosidase such as E. coli 3-D-galactosidase, maleate dehydrogenase, glucose-6-phosphate dehydrogenase, darcosoxidase, glucoamylase, acetylcholinesterase, catalase, (4) Pancreatic phosphatase such as small intestine alfa lipophosphatase and Escherichia coli alba lipophosphatase.
- phospholipases such as: lf ⁇ , 4-methylphenylphosphoric acid, etc., phosphorylation phenotypes, such as dinitrophenylphosphonate, etc. It can be measured by the generated light, luminescence, etc., using a substrate such as a DNA probe, an enzymatic cycling system using NADP, a luciferin derivative, or a dioxetane probe. Noreciferin and luciferase systems can also be used. Since it reacts with hydrogen peroxide using hydrogen peroxide to generate oxygen, the oxygen can also be drained at an electrode or the like.
- the electrode may be a glass electrode, an ion electrode using a hardly soluble metal, a compact electrode, a polymer membrane electrode, or the like.
- the enzyme label can be replaced with a biotin-labeled enzyme and enzyme-labeled avidin (streptavidin).
- the sign can also indicate several different views. Such multiple measurements can be made fiber-wise, 'or non-consecutively, and simultaneously or separately.
- a signal is formed by using 4-hydroxyphenylacetic acid, 1,2-phenylenediamine, tetramethinolebenzidine and the like, and horseradish peroxidase, campbelliferyl galactoside, nitrophenyl galactoside and the like.
- Enzymes such as S-D-galactosidase, glucose-6-phosphate and dehydrogenase! ⁇ Combination
- quinol compounds such as hydroquinone, hydroxybenzoquinone, and hydroxyanthraquinone, thiolyl conjugates such as lipoic acid and daltathione, phenol-inducing compounds, and ferrocene-inducing compounds can be formed by the action of enzymes and the like. With the use of power
- fluorescent substance or the chemiluminescent compound examples include fluorescein salts, such as rhodamine B isothiosinate, and rhodamine inducers such as tetramethyl-l-damin isothiocyanate, dansyl chloride lid, dansyl noreoli ,, de, full-blown resamine, phycobiliprotein, acridinium salt, luminol such as lumifurin, noresiferase, and aequorin, imidazole, oxalate, rare ⁇ 11 chelate compound, coumarin reference, etc. Is mentioned.
- Labeling can be carried out using a reaction between a thiol group and a maleimide group, a reaction between a pyridyl disulfide group and a thiol group, a reaction between an amino group and an aldehyde group, and the like.
- a condensing agent that can be used for producing the above-described insoluble complex, a condensing agent that can be used for binding to a carrier, and the like can be used.
- condensing agent examples include formaldehyde, glutaraldehyde, hexamethylene diisocyanate, hexamethylene diisothiocyanate, ⁇ , ⁇ '-polymethylene bis-acetamide, ⁇ , ⁇ '-ethylene bismaleimide, ethylene glycol —Rubis succinimidyl succinate, bis diazobenzidine, tolethyl-3- (3-dimethylaminopropyl) carbodiimide, succinimidyl 3- (2-pyridyl dithio) probionet (SPDP), N-succinimidyl 4 -(N-maleimide methyl) cyclohexane-1-carboxylate (SMCC), N-sulfosuccinimidyl 4--(N-maleimide methyl) cyclohexane-tricarboxylate, N-succinimidyl (4- (Acetyl acetyl) Amino benzoate, N-
- a labeled antibody such as a monoclonal antibody in which a substance to be measured is labeled with an enzyme or the like can be sequentially reacted with an antibody bound to a carrier, or simultaneously. You can also. It depends on the type of carrier system selected.
- sensitized plastic or other beads first transfer the labeled antibody, such as a monoclonal antibody labeled with an enzyme, to a suitable test tube together with a sample orchid containing the substance to be measured. Thereafter, the measurement can be performed by adding beads such as the sensitized plastic.
- the force used in the immunoassay is a solid support such as polystyrene, polycarbonate, polypropylene or polyvinyl balls, microspheres, and microspheres that absorb proteins such as antibodies well.
- a solid support such as polystyrene, polycarbonate, polypropylene or polyvinyl balls, microspheres, and microspheres that absorb proteins such as antibodies well.
- Various materials and forms such as plates, sticks, fine particles or test tubes can be arbitrarily selected and selected.
- the measurement can be performed in an appropriate buffer system so as to maintain the optimum pH, for example, about pH 4 to about 9.
- buffers include, for example, acetate buffer, citrate buffer, phosphate buffer, tris buffer, triethanolamine buffer, borate buffer, glycine buffer, carbonate buffer And Tris-HCl buffer. Buffers can be used by mixing them at any ratio.
- the antigen-antibody reaction can be performed at i3 ⁇ 4g between about 0 and about 60 ° C.
- Antibodies such as monoclonal antibodies labeled with enzymes, etc. and antibodies bound to carriers, and incubation of the substances to be measured can be performed until they reach The solid phase and the liquid phase can be separated and the reaction can be stopped after a limited incubation process at a time point earlier than when the ⁇ fi is achieved.
- the ability to measure the presence of enzymes and other markers is powerful.
- the measurement operation can be powerfully performed using an automated measurement device, and the display signal generated by the action of a substrate or nitrogen is converted using a luminescence detector, a photo detector, or the like. Detect and measure Can also be. Used in antigen-antibody reactions!
- EDTA ethylenediaminetetraacetate
- a blocking treatment commonly used in the art or known to those skilled in the art to prevent an unusual binding reaction for example, normal serum proteins from mammals, albumin, skim milk, milk fermentation Can be treated with substances, collagen, gelatin, etc. These methods are not particularly limited and can be used as long as the purpose is to prevent an unusual binding reaction.
- any form of staying night, colloid separation, or a filler sample can be used.
- a sample derived from a living organism for example, thymus, testis, intestine, kidney, brain , Breast cancer, ovarian cancer, colorectal cancer, blood, serum, plasma, synovial fluid, cerebrospinal fluid, serum, bile fluid, saliva, amniotic fluid, urine, other body fluids, cell culture, tissue culture, thread And tissue biomodnates, biopsy samples, tissues, cells and the like.
- a sample derived from a living organism for example, thymus, testis, intestine, kidney, brain , Breast cancer, ovarian cancer, colorectal cancer, blood, serum, plasma, synovial fluid, cerebrospinal fluid, serum, bile fluid, saliva, amniotic fluid, urine, other body fluids, cell culture, tissue culture, thread And tissue biomodnates, biopsy samples, tissues, cells and the like.
- Epitope mapping can also be performed using the anti-p30 antibody of the present invention (anti-human p30 antibody, anti-mouse p30 antibody, etc.), particularly a monoclonal antibody, and an antibody that recognizes each epitope can be used. For example, it can detect and measure the protein and its related peptide fragments.
- the antibody particularly a monoclonal antibody, may be used to detect (0) detect a fragmentation or cell-related disorder, abnormality and / or disease caused by the p30-Rapl interaction, or (ii) detect the p30-Rapl 3S transformation, cell migration, invasion, migration and / or metastasis due to the interaction of p30-Rapl, or the possibility thereof, and (iii) migration of cells or cells involved in the p30-Rapl interaction.
- Detect related disorders, abnormalities and Z or diseases or their potential (iv) measure the expression of the relevant p30 protein; (V) detect changes in the binding of activated Rapl to P30 And (vi) search for compounds that control the p30-Rapl binding, etc., and detect the activity of Z or (vii) the compounds that control the p30 protein production and Useful for Z or measurement. Answer, inflammation, angiogenesis, blood coagulation, healing, regenerative processes, carcinogenesis, cancer cell infiltration, metastasis, autoimmune processes, hematological processes, cell abnormalities, tissue abnormalities, rikkun It is expected that it can be used to determine the degree of mobility, invasiveness, chemotaxis and / or metastasis.
- a method for detecting and / or measuring Z or measurement of the abnormal phenomena of a tissue, a cell or a protein by the protein can be used.
- the compounds found by the screening method of the present invention have effects such as suppression of cytoplasm, suppression of cell migration, suppression of immunity, suppression of cytokine production, suppression of apoptosis occurrence, suppression of cell proliferation, and the like. Therefore, those compounds are anti-inflammatory, immune disease cure; ⁇ IJ However, it can be used as a cancer metastasis inhibitor.
- the effects of these compounds can be confirmed by the following methods. They are not intended to limit, or to limit, the scope of the invention disclosed herein.
- Test for pyloric ligation ulcer can be performed according to the description on page 249 of Reference 3.
- Model preparation Rats (140 to 200 g) are fasted for 48 hours or 72 hours (free drinking), then open under anatomical anesthesia and ligated the pylorus. After closing the abdomen, put it under fasting.
- Administration of the test substance Immediately after ligation of the pylorus, it is administered into the work space or into the duodenum.
- Cleavage method 13 to 17 hours later, lethal under anesthesia, and fix the removed stomach with a 10% buffered formalin water scythe.
- Rats' limbs are tied to a wire mesh, and cold water is applied to the lower sternum in an upright position.
- test substance Intra-oral or oral administration 10 minutes before restraint in water.
- Words ⁇ 1 method After completion of water immersion restraint, lethal under anesthesia, and perform in the same manner as in the above [1] (1) Hffi method.
- Rats (22 to 230 g) are fasted for 24 hours, and then indomethacin (Sigma) 30 mg / kg is administered subcutaneously.
- test substance Administer orally orally 10 minutes before indomethacin administration. Aspect: 8 hours after administration of indomethacin, the animal is sacrificed under anesthesia, and the procedure is performed in the same manner as in [1] (1).
- Rats (Wistar male) are fasted for 24 hours and then subcutaneously administered with Cysteamine 300-400 mg / kg.
- test substance Administer intraperitoneally or orally 10 minutes before administration of indomethacin.
- Language 18 hours after cysteamine administration, the animals were sacrificed under anesthesia, and the above [1] (1)
- Testing for ulcers due to sex substances can be performed according to the method described in Ref. 3, page 251.
- Rats are fasted for 24 hours ⁇ After 7k, orally administer pure ethanol, 0.6N HCU 25% NaCl, 80mM St-succinic acid or high.
- Administration of test substance Intra-oral administration or oral administration 30 minutes before administration of the active substance.
- the test for acetic acid ulcer can be performed according to the method described in the preparation of a model on page 251 of Reference 3.
- Animal model Rats are laparotomized under ether anesthesia and 0.04 to 0.06 ml of 20% acetic acid solution is injected submucosally at the border of the forestomach and glandular stomach.
- Test substance Administer mouth by mouth for 14 days from the day after acetic acid injection.
- Method 5 On the day after the last administration of the test substance, the animal is sacrificed under anesthesia, and the evaluation is performed in the same manner as in the evaluation method in [1] (1).
- Test for ulcer size can be performed according to the method described in Reference 5.
- Model preparation Rats are allowed to freely drink 3% DSS (dextran sodium sodium salt) aqueous solution for 11 days and then 1% DSS aqueous solution for 14 days.
- DSS extract sodium sodium salt
- Test substance administration Repeated oral administration once daily for 14 days during 1% DSS scythe administration o
- the test for Crohn's disease can be performed according to the method described in Reference 6.
- Rats are injected with TNBS (160 mg / kg in 50% ethanol) from the terminal ileum to produce small i ⁇ .
- test substance Repeat oral administration once a day for 7 days after production of enteritis.
- Appraisal method 7 days after the preparation of enteritis, the animals are sacrificed under anesthesia, and a histopathological examination (visual observation) is performed. In addition, formalin-fixed E-stained specimens are prepared (Ref. 44, p. 10), and pathological examination (microscopic observation) is performed. For each lesion found in both ⁇ ⁇ ⁇ , none: 0, minor: 0.5, mild: 1.0, moderate: 2.0, altitude: 3.0 After quantification, tabulate the numerical values for each group and compare between the test substance administration group and the non-administration group. To compare.
- C0PD chronic obstructive collapse disease
- Model construction Guinea pigs are exposed to commercial cigarettes for 30 minutes / day, 5 days / week for 4 weeks using cigarettes (INH06-CIGR01, Inc. I.P.S.).
- Test substance administration Repeat oral administration once a day during the 4-week cigarette smoke exposure period.
- ffi's method After termination of the administration period, the animals are sacrificed under anesthesia, and the lungs are subjected to histopathological examination (visual observation). In addition, formalin-fixed itHE-stained paper woven specimens are prepared (Ref. 19, page 10) and pathological examination (microscopic observation) is performed. For each disease observed in both tests, none was identified: 0, minor: 0.5, mild: 1.0, moderate: 2.0, and altitude: 3.0. After quantification, tabulate the values for each group and compare between the test substance administration group and the non-administration group.
- Model preparation Mice (C57BL / 6N, early) 5 ⁇ 10 4 cells / 0.2 ml of B16 mouse melanoma cell suspension are administered to the tail vein.
- test substance Repeated oral administration or intranasal administration from the day of B16 cell administration to 21 days later o
- Advisory method B16 cells administered 21 days after administration, killed under anesthesia, and fixate the removed lungs in 10% of the formalin-water for overnight. Slice the fixed specimen and visually count the number of metastatic foci of B16 cells. The number of metastatic foci is compared between the test substance administration group and the non-administration group.
- the test for epidermal dermatitis can be performed as described in reference 14.
- mice (BALB / C) are actively sensitized by injecting DNP-OVA + Alum (Dini tropanol-Ovalbu min + Aluminum hydroxide gel) into the air. 14 days after sensitization Apply DNFB (Dini trofluorobenzene) to the auricle of the ear.
- DNP-OVA + Alum Di tropanol-Ovalbu min + Aluminum hydroxide gel
- Administration of test substance Repeated oral or intracavitary administration for three periods, from sensitization to challenge, from challenge to testing, or from sensitization to testing.
- ⁇ iffi method Measure the thickness of the pinna at 1 hour, 24 hours and 8 days after induction. The pinna thickness is compared between the test substance-administered group and the non-administered group.
- Tests for rhergolytic rhinitis can be performed as described on page 225 of Reference 2.
- the test for asthma can be performed as described in reference 16.
- Model preparation Guinea pigs (Hartley strain) are sensitized by intravenously injecting 0.5 ml OVA + Alum (10 i OVA + lOmgAlum) into Dayl and Dayl4.
- Test substance administration The test substance is orally administered 14 days after the final sensitization.
- Advisory method 30 minutes after administration of the test substance, 10 mg / kg pyrilamine (a histamine antagonist) is administered into the gut. Thirty minutes later, a 10 mg / ml OVA PBS (-) solution is inhaled for 10 minutes to elicit. Four hours after the induction of 0VA, 400 / g / ml of methacholine was inhaled for 1 minute, and Penh was measured as a ⁇ I resistance parameter using an unrestrained respiratory function angle system, and the test substance administration group and the non-administration group were measured. Compare between.
- a rat was opened under anesthesia with ether, and the inferior vena cava was ligated.
- the heart is excised by injecting and draining from the arterial vein, ligating the superior vena cava and pulmonary vein together, and removing the heart and storing it in Ringer's lactate.
- incision is made in the skin of the right neck of the recipient rat, which is to be transplanted.
- the right external jugular vein is dissected, and the stump is cuffed.
- the right common carotid artery is dissected, and a cuff (body part 1.8 thigh, ridge, 0 / D 0.99 ridge) is attached to the stump.
- the cuff attached to the common carotid artery of the recipient is inserted into the aorta of Dona heart, ligated, and the external jugular vein of the recipient and the pulmonary artery of the donor are similarly anastomosed. After stabilization of the pulsation, the skin is sutured to wrap the transplanted heart and awaken.
- test substance Administer orally, intravenously, or intravenously once a day from the model preparation to the end of the test.
- Nomenclature Palpation of the subcutaneously transplanted heart and the survival rate are compared between the test substance-treated group and the non-treated group.
- the test for rheumatoid arthritis can be performed according to the method described in reference 18.
- Preparation of model Mouse (DBA / lJNCrj) was homogenized with FCA (Freund Complete Adjuvant) and collagen (Type II collagen K-41, containing 3 mg / ml of bone joint-derived collagen). (5 mg / ml) is injected into the tail of the mouse at 0.1 ml.
- Test substance administration Model preparation Repeat oral administration once a day from 1 week to 9 weeks later.
- Dragon's method Arthritis score ⁇ Once a week, for all finger joints of the limbs, 13 or 1 finger without arthritis score after hearing or 14 or 1 finger with mild viscera (Measured in accordance with 16. Fire score.
- the number of days of onset is defined as the number of days in which the score becomes 1 or more at the beginning of the arthritis score observation day. The arthritis score and the number of days of onset are compared between the test substance administration group and the non-administration group.
- Table 1 shows the effect tests for the target diseases other than the above.
- Table 1 Classification of disease, disease name and test method Classification Target disease name Reference number Anti-inflammatory agent or cancer metastasis inhibitor Subcutaneous edema 1
- SIRS Systemic inflammatory response syndrome
- the activity of the present invention is not limited to various medicines, for example, hearing agents (pile carcinoma agents), SS «translocation inhibitors, unrn si rmnm ⁇ mt analgesics, quenching and / or immunosuppression. It can be used in combination with an agent, and they can be used without limitation as long as they have an advantageous function, and for example, can be selected from those known in the art.
- Parenteral dosage forms may include topical, transdermal, intravenous, intramuscular, subcutaneous, intradermal, or intraepithelial administration, but can also be administered directly to the affected area, including: It is also suitable for if ⁇ .
- parenteral eg, intracellular, intratissue, intravenous, intramuscular, subcutaneous, intradermal, intrafemoral, intrathoracic, intraspinal, intravenous, intravenous, intrarectal, intraocular, rectal, ear, eyedrop or To the nose, teeth, skin and mucous membranes.
- parenteral eg, intracellular, intratissue, intravenous, intramuscular, subcutaneous, intradermal, intrafemoral, intrathoracic, intraspinal, intravenous, intravenous, intrarectal, intraocular, rectal, ear, eyedrop or To the nose, teeth, skin and mucous membranes.
- preparations include Nada preparations, dispersion preparations, semi-solid preparations, granular preparations, translators, leaching preparations, and the like.For example, tablets, coated tablets, sugar-coated preparations, Pills, troches, hard capsules
- Soft capsules microcapsules, powders, powders, powders, granules, fine granules, tablets, liquids, elixirs, emulsions, irrigants, syrups, solutions, emulsions, suspensions , Liniments, lotions, aerosols, sprays, inhalants, sprays, ointments, plasters, patches, pastes, cataplasms, creams, oils, suppositories (eg wm ⁇ ), tinctures , Skin solutions, eye drops, nasal drops, ear drops, liniments, infusions, powders for sizing, etc., Gashiyoshi desiccant, gel preparations and the like.
- compositions can be formulated according to conventional methods. For example, if necessary, a physiologically acceptable carrier, a pharmaceutically acceptable carrier, an adjuvant ij, an mM excipient, a diluent, a flavoring agent, a flavoring agent, a sweetening agent, a vehicle, a preservative, and a stabilizing agent.
- Agents binders, pH regulators, buffers, surfactants, bases, solvents, fillers, extenders, welding aids, solubilizers, isotonic agents, emulsifiers, emulsifiers, suspending agents, Dispersants, thickeners, gelling agents, curing agents, absorbents, adhesives, elastic agents, plasticizers, disintegrants, propellants, preservatives, antioxidants, sunscreens, humectants, emollients, antistatic And soothing agents are used in combination with insects or threads, and at the same time, by admixing the tannos of the present invention, and the like, the monotonada nada required for the generally accepted practice of preparations is obtained. It can be manufactured in a state.
- Formulations suitable for parenteral administration include sterile sickles of active ingredients with water or other pharmaceutically acceptable media, or suspensions, such as test agents.
- a carrier such as distilled water, Ringer's solution and menstrual solution, a suitable dispersing agent or wetting agent and a suspending agent are used, and the mixture is prepared by a method known in the art. Night, suspension, emma It is prepared in a form that can be nada like Rejon.
- aqueous solution for measurement examples include physiological fluids, isotonic solutions containing glucose and other auxiliary agents (for example, D-sorbitol, D-mannitol, sodium chloride, etc.), and pharmacologically.
- Acceptable suitable solubilizers such as alcohols (eg, ethanol), polyalcohols (eg, propylene glycol, polyethylene glycol, etc.), nonionic surfactants (eg, polysorbate)
- oily liquid examples include sesame oil and soybean oil, which may be used in combination with benzyl benzoate or benzyl alcohol as a solubilizing agent.
- buffers eg, phosphate buffer, sodium acetate buffer, etc.
- soothing agents eg, benzalkonium chloride, proforce hydrochloride, etc.
- stabilizers eg, , A human serum albumin, polyethylene glycol, etc.
- a carrier eg, benzyl alcohol, phenol, etc.
- an antioxidant such as ascorbic acid, an absorption promoter and the like.
- the prepared one-dimensional liquid is usually filled into an appropriate ampoule.
- a sterile pharmaceutically acceptable liquid such as water, ethanol or oil.
- a sterile pharmaceutically acceptable liquid such as water, ethanol or oil.
- oily vehicles or solvents used in pharmaceuticals include natural, synthetic, or semi-synthetic mono- or di- or triglycerides, natural, semi-synthetic or synthetic rechargeables, and fatty acids.
- vegetable oils such as peanut oil, corn oil, soybean oil, sesame oil and the like can be mentioned.
- this medicament can be prepared so as to normally contain the compound of the present invention in an amount of 0.1 to 10% gram MS.
- Formulations suitable for topical, e.g., oral, or rectal use include, for example, mouthwashes, dentifrices, oral [ ⁇ , inhalants, ointments, dental fillers, coatings, dental pastes, ⁇ . Mouthwashes and other dental agents are prepared by a conventional method using a pharmacologically acceptable carrier.
- a pharmacologically acceptable carrier As an oral spray or an inhalant, the compound of the present invention or a pharmacologically acceptable inert carrier may be used. It can be dissolved in a squeezer or nebulizer or administered as fine powder for inhalation to teeth.
- Ointments are prepared by conventional methods by adding commonly used bases, for example, ointment bases (white serine, paraffin, orifice oil, macrogol 400, macrogol ointment, etc.).
- Chemicals for topical application to teeth and skin can be formulated into sickles or suspensions of appropriately sterilized water or nonaqueous release agents, for example, sodium bisulfite or edetic acid.
- Preservatives including disinfecting and antifungal agents, such as buffering agents, such as Ninadium; phenylmercuric acetate or silver benzoate, benzalkonium chloride or Closhexyl hexidine; and thickening agents, such as Hypromel Rose.
- Suppositories are carriers well known in the art, preferably non-irritating suitable excipients, such as polyethylene glycols, lanolin, lactic acid, fatty acid triglycerides, etc., preferably solid at room temperature.
- the force field tube is prepared by a conventional method using a liquid that melts in a gas stream and releases the drug, etc., and is prepared by a conventional method.
- the compound of the present invention is contained in an amount of about 0.1 to 95 dragon%. Is prepared.
- the drug can be suspended or dissolved in the MJIU.
- Formulations suitable for oral use include, for example, solid compositions such as tablets, pills, capsules, powders, granules, troches, and solutions such as solutions, syrups, and suspensions.
- a formulation auxiliary known in the art and the like are used. Locks and pills can also be manufactured with enteric coating.
- the preparation When the preparation is in the form of a capsule, it may further contain a liquid carrier such as a fat or oil in addition to the above-mentioned type of material.
- a liquid carrier such as a fat or oil in addition to the above-mentioned type of material.
- it is particularly useful to bind tanno, polyisocyanate Ji ⁇ , and polyethylene glycol (PEG), whose activities are extremely low in mammals, because their toxicity is extremely low. .
- the binding of PEG has the effect of effectively reducing the heterogeneous compound's immunogenicity.
- the compound may be provided in a microforced device.
- Polymers such as PEG have amino terminal -Amino group of amino acid, ⁇ -amino group of lysine side chain, carboxyl group of aspartic acid or glutamic acid side chain, -carboxy group of carboxy terminal amino acid, or some residual asparagine, serine or threonine It can be easily attached to an activated primer of glycosino attached to the group.
- PEG useful for reacting with an amino group of a protein include carboxylic acid, an active ester called carbonate, and in particular, a leaving group having N-hydroxysuccinimide, p-ditropanol, imidazole, or the like. Or trihydroxy-2-nitrobenzene benzene-4-sulfonate.
- PEG containing an aminohydrazine or hydrazide group is useful for the reaction with aldehydes formed by periodate in proteins.
- the nucleic acid such as the DNA of the present invention is used as a therapeutic and / or prophylactic agent as described above: ⁇ , the nucleic acid can be used in insects or used in the genetic and recombination techniques as described above. It can be used by binding it to an appropriate vector such as a retrovirus-derived vector such as a virus-derived vector.
- the nucleic acid such as DMA of the present invention can be administered by a commonly known method, and may be used as it is or together with a suitable auxiliary agent or a physiologically acceptable carrier, for example, so as to promote intracellular penetration.
- Pharmaceutical thread that can be formulated and used powerfully as described above! It can be administered as a product or a pharmaceutical preparation. Also, a method known as gene therapy can be applied.
- the dose of the pirates of the present invention can be selected and administered over a wide range of doses.
- the strength, the number of doses, and the number of doses are determined according to the treatment subject's Slj, age, body weight, general health condition, diet, administration time, and administration.
- the method, release rate, drug combination, and the patient's treatment at that time may be determined according to the condition of the disease and other factors.
- their additives and preparation methods are described in, for example, the Japanese Pharmacopoeia Committee, edited by the Japanese Pharmacopoeia, No. 14 IE, published on August 27, 2001. Shikikai-net: ⁇ Kawasho Shoten; Takashi Ichigase et al.
- the activity of the present invention has a biological activity that controls (promotes or inhibits or inhibits) the interaction activity (eg, biological activity such as binding activity) between the P30 and Rapl.
- the active ingredient of the present invention includes, for example, (a) the modified p30 protein, a mutant polypeptide thereof, a partial peptide thereof, a salt thereof, or the like; (b) DNA encoding the protein; (C) an antibody of the present invention, a partial fragment thereof (including a monoclonal antibody) or an inducer thereof, and (d) an antibody between the p30 and Rapl.
- a compound or a salt thereof which has an advantageous effect on biological activity when controlling (promoting or suppressing or inhibiting) the interaction with a biological component resulting from the interaction of the compound is included.
- the activity of the present invention is expected to be useful for controlling (promoting, inhibiting, and harming) changes in various tissues or cells caused by the interaction between the P30 and Rapl.
- the active component is useful for controlling the expression of the ⁇ 30 or activated Rapl activity, and further controlling (promoting or inhibiting) inhibition of p30-Rapl binding.
- Prevention of abnormalities and / or diseases is useful for treatment. It is also expected to be useful for, for example, controlling, for example, controlling, for example, migration, invasion, migration, and / or metastasis of S-severe cells associated with p30-Rapl binding.
- the activity of the present invention is, for example, p30-Rapl binding blocking U is useful as an agent for treating inflammatory diseases, autoimmune diseases, suppression of rejection during organ transplantation, cancer, etc.
- inflammatory diseases for example, gastric ulcer, duodenal ulcer, sudden sputum, bronchitis, ARDS (acute respiratory distress syndrome), C0PD (chronic obstruction 'city disease'), septic shock, M0F (multi-organ failure), SI
- RS systemic inflammatory response disease
- systemic lupus erythematosus mixed-type conjunctivitis
- rheumatoid arthritis sigmoid disease
- rheumatic fever Goodpastia's disease
- Graves' disease Hashimoto's disease
- Addison's disease autoimmune hemolytic anemia
- idiopathic Transplant to treat purpura, myasthenia gravis, ulcerous large ⁇ , Crohn's disease, exchangeable ophthalmitis, multiple sclerosis, psoriasis, allergic rhinitis, asthma, etc. It is expected that it can be used for pretreatment, post-transplant administration, and further for suppressing carcinogenesis and metastasis.
- the dose of the compound or a salt thereof (for example, the compound of the formula (D) or the like) which promotes or inhibits the interaction and / or binding between Rapl and p30 of the present invention depends on the target disease, target of administration, administration route and the like.
- Ji ⁇ administered orally is administered at 10 g to 10 g / kg, preferably 100 zg to lg / kg, more preferably lmg to 100 mg / kg.
- lg to lg / kg Preferably, it is administered at 10 ⁇ g to 100 mg / kg, more preferably at 100 g to 10 mg / kg, administered within the space: ⁇ is l / g to 10 g / kg, preferably 10 ⁇ g to lg / kg, More preferably, the dose is 100 to 100 mg / kg.
- GST-Rapl a protein in which the N-terminal side of Rapl was fused with GSH (glutathione-S-transferase) was produced in Escherichia coli, and purified using a gnoretathion binding force ram. Further, a Myc-p30 gene having a Myc peptide added to the N-terminal side of p30 cDNA was transfected into COS cells to express p30; thus, a solubilized product was prepared.
- GST-Rapl Since apl becomes activated when bound to GTP and becomes inactivated when bound to GDP, GST-Rapl is bound to GTPgS and GDPbS, respectively, and activated and inactivated types are prepared. It was mixed with a COS cell lysate containing p30. After inverting and mixing at 4 ° C for 2 hours, daltathione Itoyoshigo beads were added to recover GST-Rapl. Detection of myc-p30 bound to Rapl was performed by using an expanded yc mouse IgG2a antibody (Cell Signaling) as the primary antibody and HRP-labeled anti-mouse IgG (Sigma) as the secondary antibody.
- IgG2a antibody Cell Signaling
- HRP-labeled anti-mouse IgG Sigma
- p30 specifically binds to activated Rapl. From the property of binding to activated Rapl, p30 was considered to be a molecule that functions with the activation of Rapl. Difficult case 2
- RNA is extracted from brain, heart, lung, liver, kidney, and spleen, cDNA is synthesized, and p30 (P) and Norel (N) cDNA are synthesized by PCR Detected ( Figure 3A).
- Glucose triphosphate flfcR enzyme G3PDH was used as a control for mRNA amount.
- G3PDH Glucose triphosphate flfcR enzyme
- p30 was found to be myeloid (HL60, U937), T lymphocyte (Jurkat, Molt4), and B lymphocyte (BaF3, A20, Nalm6), but not in melanocytic cells (B16).
- Norel was not expressed in these cells, and expression was confirmed in melanoma cells (B16).
- the undifferentiated myeloid cell line HL60 was also confirmed to have the ability to differentiate into neutrophils by retinoic acid treatment.
- a monoclonal antibody was prepared to examine the expression of the P30 protein.
- Mouse p30 cDNA was subcloned into pGEX vector (Amersham Pharmacia), and after introduction of E. coli (BL21), GST-mp30 in which GST was fused to the N-terminal of mp30 was produced. Guiding the off to BL21 LB ⁇ land 40 (grown at 30 ° C, IPTG and (0. 2 mM, Amersham Pharmacia) was added at which point 0D 6 .. 0. 5, and further 4 hours i ⁇ . Precipitate the precipitate by spinning 6 000 times, wash once with PBS, suspend with 5 ml of PBS, and output with an ultrasonic crusher (Tomisei, UD-200) 6, 4 times for 15 seconds.
- the supernatant was bound to a glutathione column (Amersham Pharmacia), washed with 100 ml of PBS, eluted with glutathione (5 mM), and dialyzed against PBS to obtain a purified antigen.
- MBP-hp30 fused with MBP maltose-binding protein was produced and purified in E. coli and used.
- human p30 cDNA was subcloned into a pMAL vector (New England Biolabs) to prepare a fusion protein with maltose binding protein (pML Protein Fusion and Purification System, New England Biolabs).
- MBP-hp30 (0.2 mg / 0.2 ml / well) was immobilized on a 96-well plate, and the antibody in the culture supernatant was detected by the sandwich method.
- FIG. 3B shows the results of Western plots using anti-p30-specific antibody Ell. 2 against blood, immune system cell lines, and T lymphocytes and B lymphocytes purified from lymph nodes (FIG. 3B).
- HL60 cells treated with retinoic acid and separated into neutrophils HL60 RA
- cells differentiated into macrophages by stimulation with vitamin D3 (ImM) and TPA (10 ng / ml) HL60 D3 + In T
- ImM vitamin D3
- TPA 10 ng / ml
- p30 is activated Rapl (RaplV12) ⁇ ⁇ ⁇
- Rapl Rapl
- ProB cell line expressing human LFA-1 BAF cells expressing both p30, Rap1V12, and RaplV12 and p30 were prepared, and cell migration on ICAM-1 was measured. did.
- a protein in which a human ICAM-1 extracellular region was fused with a human immunoglobulin Fc region (hICAM-Fc) was used as a ⁇ ICAM-l.
- hICAM-Fc human immunoglobulin Fc region
- BAF cells prepared by immobilizing ICAM-I (0.1 mg / ml) on a temperature control plate having a diameter of 6 cni were added thereto, and videotaped at 37 ° C for 20 minutes.
- the distance traveled was measured for 20 cells and the average velocity was calculated.
- RaplV12 increased the cell migration rate on ICAM-1, and P30 further enhanced its effect (Fig. 4).
- p30RBDm the RBD domain mutant of p30 ( p30RBDm).
- p30RBDm is a mutant in which the seven amino acids conserved in the RBD domain, i.e., lysine 123, 124 arginine, 135 lysine, 154 lysine, 155 lysine, 160 aspartic acid, and 161 asparagine, are substituted with alanine It is.
- This p30RBDm is expressed in the same way as the wild type, but cannot bind to GTP 'Rapl, unlike Yongzong.
- RaplV12 and p3 ORBDm were expressed in BAF cells, and the migration speed on ICAM-1 was measured. As a result, no enhancement effect was observed. Therefore, the effect of p30 on promoting cell migration by RaplV12 was required to bind to Rapl.
- the cells were labeled with a fluorescent dye using BCECF-AM (Molecular Probe), and incubated at 37 ° C for 30 minutes on a plate on which IC layer-1 (0.1 mg / ml) was immobilized.
- the number of input cells and the number of cells remaining after washing the plate at least 3 times) were measured with a fluorescence reader (Cytofluor 4000, Persepetive Biosystems), and the ratio of the number of input cells to the number of input cells was measured.
- Adhesive activity As a result, it was evident that gFA activity of LFA-1 against ICAM-1 increased depending on the level of p30 expression in 3A9T cells.
- LFA-1 / ICAM-13 ⁇ 4 induced by TCR stimulation is evident from the activation of Rapl and the complete inhibition of Rapl-specific expression of Spa-1. I have. Therefore, if p30 is involved in ⁇ downstream of Rapl, LFA-1 / ICAM-13 ⁇ 4 »is expected to be suppressed. Therefore, a mutant of p30 was created, and a mutant (deltaNp30) that functions as a dominantly suppressed type was created. dletaNp30 was prepared by deleting 100 amino acids from the N-terminus of p30. After transfection into 3A9T cells, TCR-stimulated LFA-1 / ICAM-13 ⁇ 43 ⁇ 4 was examined. As a result, as shown in FIG. 6C, it was determined that deltaNp30 was able to inhibit the adhesion of LFA-1 to ICAM-1 by TCR stimulation in a ⁇
- PGEX-3X (Amersh am Pharmacia Biotech) was used as a plasmid for production of fusion protein of GST-Rapl.
- the coding sequence of Rapl represented by the rooster sequence number: 1 was inserted between the BamHI and EcoRI restriction enzyme sites of the vector.
- the base sequence represented by SEQ ID NO: 1 was inserted so that a 5-base pair CC was inserted before the terminal ATG.
- the link between the BamHI site of the vector and Ra Pi was 5 ′ ⁇ -GGATCCCCATG- ⁇ 3 '.
- the obtained plasmid for producing fusion protein of GST-Rapl was transfected into E. coli.
- Glutathione Sepharose 4B beads (Amersham) were added to the supernatant obtained by centrifugation of the pool, and the mixture was reacted at 4 ° C for 1 hour to prepare GST_Rapl beads.
- Plasmid p30-Myc tag was introduced into 70% confluent 293T cells by electroporation. The transfected cells were cultured for 2 days and collected by centrifugation. The collected cells were lysed with Lysis buffer, and the supernatant was collected after centrifugation to obtain p30 Lysate.
- the hydrate (compound 1) was added. After the reaction, the beads were washed four times with a Lysis buffer, and 25 L of a normal sample buffer was added to the beads precipitated by centrifugation to prepare a sample for SDS-PAGE. This sample was subjected to stamp lotting by SDS-PAGE.
- a film for chemiluminescence (Amersham) was performed by ECL chemiluminescence method. Exposure was detected.
- the band obtained by exposing the film was converted using image analysis software (win Roof, Mitani Shoji). That is, the band of P30 to be compared was extracted by the binarization process, and the volume of the category of luminance X area was compared.
- the activity can be screened using various diaminotrifluoromethylpyridine derivatives disclosed in, for example, JP-A-6-263735.
- Example 7
- the gene for human p30 was introduced into 3A9T cells.
- 3A9T cells and cells transfected with p30 (3A9 / p30) were fixed with 3.3% paraformaldehyde for 15 minutes at room temperature, and then mounted on a slide coated with poly-J-gin. After washing with PBS, PBS / 0.2% ⁇ -100 supplemented with 2 mM MgCl 2 was added, and the mixture was incubated for 5 minutes. After washing with PBS, the cells were blocked with 5% goat serum for 20 minutes. Thereafter, a mouse anti-tubulin antibody (diluted 1: 500 with 1% BSA) was added, and the mixture was incubated for 1 hour.
- ⁇ cells and ⁇ 3 ⁇ 41 presenting cells is an important adhesion that allows 3 ⁇ 43 ⁇ 43 ⁇ 4 cells to be recognized, but this leakage is through the LFA-1 / IC layer-1. Therefore, the localization of # 30 and LFA-1 in this bond was examined.
- HEL hen egg lysozyme
- CH27 cells were used as APC.
- CH27 cells (lxlO 5 / ml) were added with HEL in (100 ⁇ g) and cultured for 16 hours. Then, the same number of 3A9 T cells and CH27 cells (lxlO 5 / ml) were mixed and incubated at 37 ° C for 30 minutes. 3.
- the plate was mounted on a slide coated with polylysine. After washing with PBS, PBS / 0.2% ⁇ -100 supplemented with 2 mM MgCl 2 was added and incubated for 3 minutes. After washing with PBS, the cells were blocked with 5% goat serum for 20 minutes. Rat anti- ⁇ 30 antibody (10 g / ml) (Ell.2) was added and incubated for 1 hour.o After washing 4 times with PBS / 0.1%, Alexa-546 conjugated rat anti-mouse IgG (5% with 1% BSA) A 1: 0 dilution, Molecular Probe) was added and incubated for 1 hour.
- Transgenic mice are produced by an improved method of the method of Gordon et al. (1980. Proc. Nalt. Acad. Sci. 77: 7380-7384).
- mice C57BL / 6N Crj (Nippon-chirurisuribai) were subjected to excess willow-induced treatment (administration of 5 IU of pregnant horse serum serum glutin-stimulating hormone, and 48 IU of human placental hypostimulus hormone after 48 hours). ), And mating with the same strain of male mice.
- the oviduct is removed from the female mouse with Nagina vagina, and the pronuclear stage fertilized egg is collected. Inject the prepared DNA fragment sickle (prepared to a few ng / fil with TE buffer). Cultured in implantation process after 2 3 hours ⁇ 2 Inkyubeta.
- a morphologically normal embryo is selected and transplanted into the oviduct of ffiffl pseudopregnant female mouse (Jcl: MCHC ICR) (CLEA Japan).
- Jcl MCHC ICR
- Embryo transfer to the fallopian tube is performed by incising the back of an anesthetized female mouse, removing the ovaries, making a partial incision between the fallopian tube and the magnum of the fallopian tube. This is done by injecting the filled embryo-containing culture medium, empty S, and culture medium in this order.
- the female mouse that has been sutured is placed in a vinyl isolator for isolation and breeding, spontaneously delivered, and weaned until weaning.
- no birth is observed by the afternoon of the expected birth date: ⁇ indicates that the neonate has been excised by hysterectomy, and the obtained neonate has been prepared in another isolator in advance. : Nursing on SPF).
- 3 ⁇ 4 or foster parents are used to carry out a physical examination, and the offspring whose parent's SPF is confirmed are introduced into the SPF breeding room, and gene loaf is carried out. After genetic analysis, the offspring having the introduced gene will be used to confirm the identity of the transgene to the next generation.
- Tail Fiber is cut from the tip at about 10 to 15 mm from the tip with a special scissor, which has been dry-heat sterilized in advance, and put into a sterilized Etpendorf tube. store. DNA is extracted from the cryopreserved tail yarn fiber by a protease treatment method (Amangam Bioscience: cord; 27-2537-01).
- the extracted DNA was designed side '3 immediately downstream of the vector portion and the 5' side of the p30 gene in the template the flop Lima one [each EitijieishiCGTGGACAGCAGCATGAGCAGCGGG (Rooster himself column number 1 1) and 1 ⁇ TGTGAGCCAGGGCAnGGCCACACCA (Rooster himself Using column No. 12), a mouse having the gene fragment introduced by PCR is identified. By introducing a 1144 bp fragment into this PCR, the introduction of the gene is confirmed.
- my c-tag sequence containing a start codon to enable detection of antibodies against k myc produced as a protein in cells
- the present invention provides a technique that utilizes the knowledge that the interaction between p30 and Rapl controls cell activation and lt3 ⁇ 4 transmission.
- p30-Rapl interaction control substances such as compounds that inhibit the p30-RaPi binding, and to develop screens and the like used therefor.
- Inhibitors and other p30-Rapl binding regulators can be expected as pharmaceuticals, and can be used as anti-inflammatory drugs, immunosuppressants, transplantation immunosuppressants, anticancer drugs, and the like.
- modified P30-related peptides and nucleic acids, as well as anti-p30 antibodies and the like are highly useful, for example, those that function in a predominantly suppressed form in cells and those that function to inhibit 30-Rapl binding. Utilizing this technology and knowledge, it is also possible to develop ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ .
- SEQ ID NO: 12 Description of Artificial Sequence: Ol igonucleotide to act as a primer for PCR
- SEQ ID NO: 14 Description of Artificial Sequence: Ol igonucleotide to act as a primer for PCR
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003277537A AU2003277537A1 (en) | 2002-10-30 | 2003-10-30 | REGULATION OF INTERACTION BETWEEN RAPL AND Rap1 |
US10/532,683 US20070031415A1 (en) | 2002-10-30 | 2003-10-30 | Regulation of interaction between rapl and rap1 |
EP03809869A EP1557670A4 (en) | 2002-10-30 | 2003-10-30 | REGULATION OF INTERACTIONS BETWEEN RAPL AND RAP1 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002316892 | 2002-10-30 | ||
JP2002-316892 | 2002-10-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004040302A1 true WO2004040302A1 (ja) | 2004-05-13 |
WO2004040302A8 WO2004040302A8 (ja) | 2005-03-24 |
Family
ID=32211702
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/013937 WO2004040302A1 (ja) | 2002-10-30 | 2003-10-30 | RAPL・Rap1相互作用制御 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20070031415A1 (ja) |
EP (1) | EP1557670A4 (ja) |
AU (1) | AU2003277537A1 (ja) |
WO (1) | WO2004040302A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011123795A1 (en) | 2010-04-02 | 2011-10-06 | Battelle Memorial Institute | Methods for associating or dissociating guest materials with a metal organic framework, systems for associating or dissociating guest materials within a series of metal organic frameworks, and gas separation assemblies |
WO2014050908A1 (ja) * | 2012-09-26 | 2014-04-03 | 富士フイルム株式会社 | ポリペプチド、足場組成物、軟骨組織修復用組成物、軟骨細胞培養用組成物及びグリコサミノグリカン産生促進用組成物 |
JP6616332B2 (ja) * | 2015-01-29 | 2019-12-04 | 株式会社タウンズ | マイコプラズマ・ニューモニエの免疫学的検出法及びキット |
ES2775529T3 (es) * | 2015-01-29 | 2020-07-27 | Tauns Co Ltd | Procedimiento de detección inmunológica y kit para Mycoplasma pneumoniae |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0284181A (ja) * | 1988-09-20 | 1990-03-26 | Rikagaku Kenkyusho | 癌抑制遺伝子、その単離法、それがコードするペプチド、及び抗体 |
JPH02231500A (ja) * | 1988-05-31 | 1990-09-13 | Mitsubishi Kasei Corp | 新規なgtp結合蛋白質及びその産生方法 |
EP0465913A2 (en) * | 1990-07-10 | 1992-01-15 | Ishihara Sangyo Kaisha, Ltd. | Diaminotrifluoromethylpyrimidine derivatives, process for their production and phospholipase A2 inhibitor containing them |
JPH06135934A (ja) * | 1991-12-27 | 1994-05-17 | Ishihara Sangyo Kaisha Ltd | ピリジン誘導体又はその塩を含有するホスホリパーゼ▲a2▼阻害剤、抗炎症剤又は抗膵炎剤 |
WO1998037887A1 (en) * | 1997-02-28 | 1998-09-03 | Ishihara Sangyo Kaisha Ltd. | Anticancer composition comprising a diaminotrifluoromethylpyridine derivative |
WO2001056568A1 (fr) * | 2000-01-31 | 2001-08-09 | Ishihara Sangyo Kaisha, Ltd. | Substances therapeutiques ou preventives pour maladies digestives, contenant des derives de diaminotrifluoromethylpyridine |
WO2001056570A1 (fr) * | 2000-02-01 | 2001-08-09 | Ishihara Sangyo Kaisha, Ltd. | Substances therapeutiques ou preventives pour insuffisance pulmonaire, contenant des derives de diaminotrifluoromethylpyridine |
JP2002530077A (ja) * | 1998-11-18 | 2002-09-17 | インサイト・ファーマスーティカルズ・インコーポレイテッド | 炎症関連遺伝子 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5175383A (en) * | 1989-02-17 | 1992-12-29 | President And Fellows Of Harvard College | Animal model for benign prostatic disease |
ZA915023B (en) * | 1990-07-10 | 1992-05-27 | Ishihara Sangyo Kaisha | Diaminotrifluoromethylpyridine derivatives,process for their production and phospholipase a2 inhibitor containing them |
US5767337A (en) * | 1995-07-31 | 1998-06-16 | Duke University | Creation of human apolipoprotein E isoform specific transgenic mice in apolipoprotein deficient "knockout" mice |
US6140488A (en) * | 1997-10-01 | 2000-10-31 | Zhang; Xian-Feng | Ras-binding protein (PRE1) |
US6485910B1 (en) * | 1998-02-09 | 2002-11-26 | Incyte Genomics, Inc. | Ras association domain containing protein |
US6596488B2 (en) * | 2000-03-30 | 2003-07-22 | City Of Hope | Tumor suppressor gene |
US20030144196A1 (en) * | 2001-08-21 | 2003-07-31 | Bowen Michael A. | Activated T lymphocyte nucleic acid sequences and polypeptides encoded by same |
US20050064384A1 (en) * | 2001-12-14 | 2005-03-24 | Joseph Avruch | Recruitment of mst1 or mst2 protein kinase to induce apoptosis in eukaryotic cells |
-
2003
- 2003-10-30 US US10/532,683 patent/US20070031415A1/en not_active Abandoned
- 2003-10-30 WO PCT/JP2003/013937 patent/WO2004040302A1/ja not_active Application Discontinuation
- 2003-10-30 EP EP03809869A patent/EP1557670A4/en not_active Withdrawn
- 2003-10-30 AU AU2003277537A patent/AU2003277537A1/en not_active Abandoned
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02231500A (ja) * | 1988-05-31 | 1990-09-13 | Mitsubishi Kasei Corp | 新規なgtp結合蛋白質及びその産生方法 |
JPH0284181A (ja) * | 1988-09-20 | 1990-03-26 | Rikagaku Kenkyusho | 癌抑制遺伝子、その単離法、それがコードするペプチド、及び抗体 |
EP0465913A2 (en) * | 1990-07-10 | 1992-01-15 | Ishihara Sangyo Kaisha, Ltd. | Diaminotrifluoromethylpyrimidine derivatives, process for their production and phospholipase A2 inhibitor containing them |
JPH06135934A (ja) * | 1991-12-27 | 1994-05-17 | Ishihara Sangyo Kaisha Ltd | ピリジン誘導体又はその塩を含有するホスホリパーゼ▲a2▼阻害剤、抗炎症剤又は抗膵炎剤 |
WO1998037887A1 (en) * | 1997-02-28 | 1998-09-03 | Ishihara Sangyo Kaisha Ltd. | Anticancer composition comprising a diaminotrifluoromethylpyridine derivative |
JP2002530077A (ja) * | 1998-11-18 | 2002-09-17 | インサイト・ファーマスーティカルズ・インコーポレイテッド | 炎症関連遺伝子 |
WO2001056568A1 (fr) * | 2000-01-31 | 2001-08-09 | Ishihara Sangyo Kaisha, Ltd. | Substances therapeutiques ou preventives pour maladies digestives, contenant des derives de diaminotrifluoromethylpyridine |
WO2001056570A1 (fr) * | 2000-02-01 | 2001-08-09 | Ishihara Sangyo Kaisha, Ltd. | Substances therapeutiques ou preventives pour insuffisance pulmonaire, contenant des derives de diaminotrifluoromethylpyridine |
Non-Patent Citations (1)
Title |
---|
See also references of EP1557670A4 * |
Also Published As
Publication number | Publication date |
---|---|
EP1557670A1 (en) | 2005-07-27 |
US20070031415A1 (en) | 2007-02-08 |
WO2004040302A8 (ja) | 2005-03-24 |
EP1557670A4 (en) | 2007-03-07 |
AU2003277537A1 (en) | 2004-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3837494B2 (ja) | 可溶型rageタンパク質 | |
Johnstone et al. | Characterization of mouse A33 antigen, a definitive marker for basolateral surfaces of intestinal epithelial cells | |
JP2006206587A (ja) | 新規なポリペプチド及びそれをコードする核酸 | |
WO2002006483A1 (fr) | Nouveau peptide actif sur le plan physiologique et utilisation associee | |
JP2002526028A (ja) | ヒトトール相同体 | |
JP2003116587A (ja) | ポリペプチド及び同じものをコードしている核酸 | |
US8604162B2 (en) | Collectin | |
DE69839430T2 (de) | Mit A33 verwandte Antigene und deren pharmezeutische Verwendung | |
WO2004064857A1 (ja) | ガレクチン9含有医薬 | |
JP2003180381A (ja) | 免疫関連疾患の治療のための組成物と方法 | |
JP4314386B2 (ja) | Bcl−2調節因子(BMF)配列及びアポトーシスの調節におけるそれらの使用 | |
WO2004040302A1 (ja) | RAPL・Rap1相互作用制御 | |
JP2004244411A (ja) | ガレクチン9含有医薬 | |
JPH05501951A (ja) | 組換えヒト甲状腺ペルオキシダーゼ | |
WO2007037245A1 (ja) | 血管新生抑制作用を有するポリペプチド | |
JP4171228B2 (ja) | 可溶型rage測定法 | |
JP2004166695A (ja) | RAPL・Rap1相互作用制御 | |
JP4188720B2 (ja) | 新規スクリーニング方法 | |
DE69932644T2 (de) | Menschliches Protein mit in vitro antiproliferativer Aktivität. | |
WO2008066483A1 (en) | Use of nalp5 in methods for diagnosis and therapy of parathyroid related disorders | |
JP2006180813A (ja) | アミノペプチダーゼoおよびその利用 | |
DE69937756T2 (de) | Menschliches Prostasin-ähnliches Protein und dafür kodierende Nukleinsäure | |
JP2003180384A (ja) | Adamts−15,−16,−17,−18及び−19 | |
JP4676608B2 (ja) | 新規タヒキニン様ポリペプチドおよびその用途 | |
WO2006009309A1 (ja) | ガレクチン9結合タンパク質因子 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WR | Later publication of a revised version of an international search report | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003809869 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007031415 Country of ref document: US Ref document number: 10532683 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2003809869 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 10532683 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2003809869 Country of ref document: EP |